

# Suppression of Exosomal PD-L1 Induces Systemic Anti-

Cell

177, 414-427.e13

DOI: [10.1016/j.cell.2019.02.016](https://doi.org/10.1016/j.cell.2019.02.016)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Immune checkpoint inhibitors: a new era for esophageal cancer. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 731-738.	1.1	9
2	Role of the Exosome in Ovarian Cancer Progression and Its Potential as a Therapeutic Target. <i>Cancers</i> , 2019, 11, 1147.	1.7	54
3	Pseudoprogression: an indicator for cure in combined immunotherapy?. <i>Immunotherapy</i> , 2019, 11, 1087-1093.	1.0	6
4	Effect and biomarker of Nivolumab for non-small-cell lung cancer. <i>Biomedicine and Pharmacotherapy</i> , 2019, 117, 109199.	2.5	22
5	Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. <i>Molecular Cancer</i> , 2019, 18, 125.	7.9	201
6	Melanoma Extracellular Vesicles Generate Immunosuppressive Myeloid Cells by Upregulating PD-L1 via TLR4 Signaling. <i>Cancer Research</i> , 2019, 79, 4715-4728.	0.4	97
7	The biological functions and clinical applications of exosomes in lung cancer. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 4613-4633.	2.4	90
8	The Mantle Exosome and MicroRNAs of <i>Hyriopsis cumingii</i> Involved in Nacre Color Formation. <i>Marine Biotechnology</i> , 2019, 21, 634-642.	1.1	25
9	New insights into extracellular vesicle biogenesis and function. <i>Journal of Cell Science</i> , 2019, 132, .	1.2	152
10	Tumor-derived extracellular vesicles: molecular parcels that enable regulation of the immune response in cancer. <i>Journal of Cell Science</i> , 2019, 132, .	1.2	52
11	Exploiting autoimmunity unleashed by low-dose immune checkpoint blockade to treat advanced cancer. <i>Scandinavian Journal of Immunology</i> , 2019, 90, e12821.	1.3	20
12	Exosomal miRNA-1231 derived from bone marrow mesenchymal stem cells inhibits the activity of pancreatic cancer. <i>Cancer Medicine</i> , 2019, 8, 7728-7740.	1.3	74
13	Mechanisms Controlling PD-L1 Expression in Cancer. <i>Molecular Cell</i> , 2019, 76, 359-370.	4.5	501
14	Extracellular Vesicles in Cancer Immune Microenvironment and Cancer Immunotherapy. <i>Advanced Science</i> , 2019, 6, 1901779.	5.6	179
15	Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients. <i>Journal of Translational Medicine</i> , 2019, 17, 355.	1.8	150
16	Dual-Locking Nanoparticles Disrupt the PD-1/PD-L1 Pathway for Efficient Cancer Immunotherapy. <i>Advanced Materials</i> , 2019, 31, e1905751.	11.1	95
17	Beyond tumor mutational burden: potential and limitations in using exosomes to predict response to immunotherapy. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 1079-1088.	1.5	15
18	The Common Costimulatory and Coinhibitory Signaling Molecules in Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Immunology</i> , 2019, 10, 2457.	2.2	16

#	ARTICLE	IF	CITATIONS
19	Exploring the key communicator role of exosomes in cancer microenvironment through proteomics. <i>Proteome Science</i> , 2019, 17, 5.	0.7	30
20	Extracellular vesicles in urologic malignancies—Implementations for future cancer care. <i>Cell Proliferation</i> , 2019, 52, e12659.	2.4	20
21	Intercellular transfer of HLA-β: its potential in cancer immunology. <i>Clinical and Translational Immunology</i> , 2019, 8, e1077.	1.7	33
22	The role of exosomal PD-L1 in tumor progression and immunotherapy. <i>Molecular Cancer</i> , 2019, 18, 146.	7.9	236
23	Engineered nanoparticles circumvent the adaptive treatment tolerance to immune-checkpoint blockade therapy. <i>Science China Chemistry</i> , 2019, 62, 1557-1560.	4.2	5
24	Circulating biomarkers predictive of tumor response to cancer immunotherapy. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 895-904.	1.5	28
25	Recent advances of exosomes in immune-mediated eye diseases. <i>Stem Cell Research and Therapy</i> , 2019, 10, 278.	2.4	61
26	The Transcription Factor Bhlhe40 Programs Mitochondrial Regulation of Resident CD8+ T Cell Fitness and Functionality. <i>Immunity</i> , 2019, 51, 491-507.e7.	6.6	148
27	Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. <i>Molecular Cancer</i> , 2019, 18, 139.	7.9	156
28	Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?. <i>Annals of Oncology</i> , 2019, 30, 1448-1459.	0.6	146
29	A good start of immunotherapy in esophageal cancer. <i>Cancer Medicine</i> , 2019, 8, 4519-4526.	1.3	67
30	Exosome-mediated communication in the tumor microenvironment contributes to hepatocellular carcinoma development and progression. <i>Journal of Hematology and Oncology</i> , 2019, 12, 53.	6.9	163
31	Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade. <i>Pharmacological Research</i> , 2019, 145, 104258.	3.1	115
32	Challenges in the Isolation and Proteomic Analysis of Cancer Exosomes—Implications for Translational Research. <i>Proteomes</i> , 2019, 7, 22.	1.7	20
33	Multiplexed immunophenotyping of circulating exosomes on nano-engineered ExoProfile chip towards early diagnosis of cancer. <i>Chemical Science</i> , 2019, 10, 5495-5504.	3.7	118
34	The Extracellular RNA Communication Consortium: Establishing Foundational Knowledge and Technologies for Extracellular RNA Research. <i>Cell</i> , 2019, 177, 231-242.	13.5	152
35	Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade. <i>RSC Advances</i> , 2019, 9, 33903-33911.	1.7	17
36	Tumor PD-L1 Induction by Resveratrol/Piceatannol May Function as a Search, Enhance, and Engage (SEE) Signal to Facilitate the Elimination of Cold, Non-Responsive Low PD-L1-Expressing Tumors by PD-L1 Blockade. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5969.	1.8	9

#	ARTICLE	IF	CITATIONS
37	Exosomes as a storehouse of tissue remodeling proteases and mediators of cancer progression. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 455-468.	2.7	22
38	The Emerging Role of GC-MSCs in the Gastric Cancer Microenvironment: From Tumor to Tumor Immunity. <i>Stem Cells International</i> , 2019, 2019, 1-9.	1.2	4
39	Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. <i>Cancers</i> , 2019, 11, 1926.	1.7	27
40	Basis of PD1/PD-L1 Therapies. <i>Journal of Clinical Medicine</i> , 2019, 8, 2168.	1.0	85
41	Reprogramming extracellular vesicles with engineered proteins. <i>Methods</i> , 2020, 177, 95-102.	1.9	16
42	Exosomes, microvesicles, and their friends in solid tumors. , 2020, , 39-80.		3
43	Tumor-derived exosomes (TDEs): How to avoid the sting in the tail. <i>Medicinal Research Reviews</i> , 2020, 40, 385-412.	5.0	35
44	Extracellular vesicles as biomarkers and therapeutic targets for cancer. <i>American Journal of Physiology - Cell Physiology</i> , 2020, 318, C29-C39.	2.1	162
45	The cancer exosomes: Clinical implications, applications and challenges. <i>International Journal of Cancer</i> , 2020, 146, 2946-2959.	2.3	80
46	New Approaches on Cancer Immunotherapy. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a036863.	2.9	17
47	Exosomes derived from maxillary BMSCs enhanced the osteogenesis in iliac BMSCs. <i>Oral Diseases</i> , 2020, 26, 131-144.	1.5	33
48	Personalized detection of circling exosomal PD-L1 based on Fe <sub>3</sub> O <sub>4</sub> @TiO <sub>2</sub> isolation and SERS immunoassay. <i>Biosensors and Bioelectronics</i> , 2020, 148, 111800.	5.3	150
49	Homogeneous, Low-volume, Efficient, and Sensitive Quantitation of Circulating Exosomal PD-L1 for Cancer Diagnosis and Immunotherapy Response Prediction. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 4800-4805.	7.2	159
50	Large extracellular vesicles: Size matters in tumor progression. <i>Cytokine and Growth Factor Reviews</i> , 2020, 51, 69-74.	3.2	41
51	Exosomal PD-L1 functions as an immunosuppressant to promote wound healing. <i>Journal of Extracellular Vesicles</i> , 2020, 9, 1709262.	5.5	67
52	Immunoregulatory Potential of Exosomes Derived from Cancer Stem Cells. <i>Stem Cells and Development</i> , 2020, 29, 327-335.	1.1	11
53	Biomimetic cell-derived nanocarriers for modulating immune responses. <i>Biomaterials Science</i> , 2020, 8, 530-543.	2.6	29
54	Proteolytic processing of PD-L1 by ADAM proteases in breast cancer cells. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 43-55.	2.0	56

#	ARTICLE	IF	CITATIONS
55	B7-H3 in Medulloblastoma-Derived Exosomes; A Novel Tumorigenic Role. International Journal of Molecular Sciences, 2020, 21, 7050.	1.8	12
56	Exosomes from different cells: Characteristics, modifications, and therapeutic applications. European Journal of Medicinal Chemistry, 2020, 207, 112784.	2.6	59
57	Extracellular vesicles-based drug delivery systems for cancer immunotherapy. Journal of Controlled Release, 2020, 328, 562-574.	4.8	18
58	&lt;p&gt;Exosome: A Review of Its Classification, Isolation Techniques, Storage, Diagnostic and Targeted Therapy Applications&lt;/p&gt;. International Journal of Nanomedicine, 2020, Volume 15, 6917-6934.	3.3	564
59	Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy. Science Translational Medicine, 2020, 12, .	5.8	142
60	Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients. Journal of Nanobiotechnology, 2020, 18, 151.	4.2	49
61	In vivo imaging of long-term accumulation of cancer-derived exosomes using a BRET-based reporter. Scientific Reports, 2020, 10, 16616.	1.6	17
62	Emerging Prospects of Exosomes for Cancer Treatment: From Conventional Therapy to Immunotherapy. Advanced Materials, 2020, 32, e2002440.	11.1	160
63	Coptisine Blocks Secretion of Exosomal <i>CCT3</i> from Cancer-Associated Fibroblasts to Reprogram Glucose Metabolism in Hepatocellular Carcinoma. DNA and Cell Biology, 2020, 39, 2281-2288.	0.9	20
64	Immuno-Surgical Management of Pancreatic Cancer with Analysis of Cancer Exosomes. Cells, 2020, 9, 1645.	1.8	5
65	The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells. Cell Communication and Signaling, 2020, 18, 112.	2.7	62
66	&lt;p&gt;Glucometabolic Reprogramming in the Hepatocellular Carcinoma Microenvironment: Cause and Effect&lt;/p&gt;. Cancer Management and Research, 2020, Volume 12, 5957-5974.	0.9	21
67	Applying CRISPR/Cas13 to Construct Exosomal PD&#x2013;L1 Ultrasensitive Biosensors for Dynamic Monitoring of Tumor Progression in Immunotherapy. Advanced Therapeutics, 2020, 3, 2000093.	1.6	26
68	Tumor-Derived Extracellular Vesicles and the Immune System&#x2013;Lessons From Immune-Competent Mouse-Tumor Models. Frontiers in Immunology, 2020, 11, 606859.	2.2	13
69	Exosomes and breast cancer drug resistance. Cell Death and Disease, 2020, 11, 987.	2.7	103
70	High-throughput single-EV liquid biopsy: Rapid, simultaneous, and multiplexed detection of nucleic acids, proteins, and their combinations. Science Advances, 2020, 6, .	4.7	73
71	Technical Advancements for Studying Immune Regulation of Disseminated Dormant Cancer Cells. Frontiers in Oncology, 2020, 10, 594514.	1.3	10
72	Immune Checkpoint Blockade Therapy for Hepatocellular Carcinoma: Clinical Challenges and Considerations. Frontiers in Oncology, 2020, 10, 590058.	1.3	5

#	ARTICLE	IF	CITATIONS
73	Overcoming Immune Evasion in Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8984.	1.8	88
74	Stresses in the metastatic cascade: molecular mechanisms and therapeutic opportunities. <i>Genes and Development</i> , 2020, 34, 1577-1598.	2.7	19
75	Isolation and characterization of exosomes for cancer research. <i>Journal of Hematology and Oncology</i> , 2020, 13, 152.	6.9	218
76	Salivary gland cancer in the era of immunotherapy: can we exploit tumor microenvironment?. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 1047-1059.	1.5	11
77	A Clinician's Guide to Cancer-Derived Exosomes: Immune Interactions and Therapeutic Implications. <i>Frontiers in Immunology</i> , 2020, 11, 1612.	2.2	21
78	MicroRNA-138-5p Suppresses Non-small Cell Lung Cancer Cells by Targeting PD-L1/PD-1 to Regulate Tumor Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 540.	1.8	34
79	Cytotrophoblast extracellular vesicles enhance decidual cell secretion of immune modulators via TNF-alpha. <i>Development (Cambridge)</i> , 2020, 147, .	1.2	12
80	Focus on the morphogenesis, fate and the role in tumor progression of multivesicular bodies. <i>Cell Communication and Signaling</i> , 2020, 18, 122.	2.7	22
81	Recent Advances in the Use of Exosomes in Sjögren's Syndrome. <i>Frontiers in Immunology</i> , 2020, 11, 1509.	2.2	27
82	Biology and therapeutic potential of mesenchymal stem cell-derived exosomes. <i>Cancer Science</i> , 2020, 111, 3100-3110.	1.7	130
83	Exosomal LGALS9 in the cerebrospinal fluid of glioblastoma patients suppressed dendritic cell antigen presentation and cytotoxic T-cell immunity. <i>Cell Death and Disease</i> , 2020, 11, 896.	2.7	61
84	Role of microenvironmental acidity and tumor exosomes in cancer immunomodulation. <i>Translational Cancer Research</i> , 2020, 9, 5775-5786.	0.4	9
85	Tailoring precision immunotherapy: coming to a clinic soon?. <i>ESMO Open</i> , 2020, 5, e000631.	2.0	8
86	New Insights into the Role of Sphingolipid Metabolism in Melanoma. <i>Cells</i> , 2020, 9, 1967.	1.8	15
87	The evolving translational potential of small extracellular vesicles in cancer. <i>Nature Reviews Cancer</i> , 2020, 20, 697-709.	12.8	295
88	Infectious Tolerance as Seen With 2020 Vision: The Role of IL-35 and Extracellular Vesicles. <i>Frontiers in Immunology</i> , 2020, 11, 1867.	2.2	7
89	Personalized Immuno-Oncology. <i>Medical Principles and Practice</i> , 2021, 30, 1-16.	1.1	25
90	Extracellular Vesicles in the Development of Cancer Therapeutics. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6097.	1.8	40

#	ARTICLE	IF	CITATIONS
91	Immune suppressed tumor microenvironment by exosomes derived from gastric cancer cells via modulating immune functions. <i>Scientific Reports</i> , 2020, 10, 14749.	1.6	44
93	Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles. <i>Journal of Extracellular Vesicles</i> , 2020, 8, e001113.		32
94	Extracellular Vesicles Orchestrate Immune and Tumor Interaction Networks. <i>Cancers</i> , 2020, 12, 3696.	1.7	12
95	Extracellular Vesicles in Hematological Malignancies: From Biomarkers to Therapeutic Tools. <i>Diagnosics</i> , 2020, 10, 1065.	1.3	20
96	An insight into small extracellular vesicles: Their roles in colorectal cancer progression and potential clinical applications. <i>Clinical and Translational Medicine</i> , 2020, 10, e249.	1.7	12
97	COVID-19 therapy with mesenchymal stromal cells (MSC) and convalescent plasma must consider exosome involvement: Do the exosomes in convalescent plasma antagonize the weak immune antibodies?. <i>Journal of Extracellular Vesicles</i> , 2020, 10, e12004.	5.5	43
98	ExoHCR: a sensitive assay to profile PD-L1 level on tumor exosomes for immunotherapeutic prognosis. <i>Biophysics Reports</i> , 2020, 6, 290-298.	0.2	2
99	Versatile Role of Rab27a in Glioma: Effects on Release of Extracellular Vesicles, Cell Viability, and Tumor Progression. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 554649.	1.6	9
100	Tiny Actors in the Big Cellular World: Extracellular Vesicles Playing Critical Roles in Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7688.	1.8	12
101	Moderne Aspekte der Immuntherapie mit Checkpoint-Inhibitoren bei Melanom. <i>Karger Kompass Dermatologie</i> , 2020, 8, 92-101.	0.0	0
102	Liquid Biopsies to Evaluate Immunogenicity of Gynecological/Breast Tumors: On the Way to Blood-Based Biomarkers for Immunotherapies. <i>Breast Care</i> , 2020, 15, 470-480.	0.8	11
103	Hyperthermia Targeting the Tumor Microenvironment Facilitates Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2020, 11, 595207.	2.2	52
104	Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 569219.	1.8	59
105	Preparation of engineered extracellular vesicles with full-length functional PD-1 membrane proteins by baculovirus expression system. <i>Biochemical and Biophysical Research Communications</i> , 2020, 526, 967-972.	1.0	7
106	Immune Escape Mediated by Exosomal PD-L1 in Cancer. <i>Advanced Biology</i> , 2020, 4, e2000017.	3.0	19
107	Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC. <i>Biomedicine and Pharmacotherapy</i> , 2020, 127, 109996.	2.5	35
108	Acquired Resistance to Immune Checkpoint Blockade Therapies. <i>Cancers</i> , 2020, 12, 1161.	1.7	9
109	The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses. <i>Frontiers in Immunology</i> , 2020, 11, 940.	2.2	423

#	ARTICLE	IF	CITATIONS
110	CRISPR screen in mechanism and target discovery for cancer immunotherapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188378.	3.3	25
111	Exosomes as drug carriers for cancer therapy and challenges regarding exosome uptake. <i>Biomedicine and Pharmacotherapy</i> , 2020, 128, 110237.	2.5	131
112	Biogenic nanoparticles as immunomodulator for tumor treatment. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2020, 12, e1646.	3.3	21
113	Immune checkpoint signaling and cancer immunotherapy. <i>Cell Research</i> , 2020, 30, 660-669.	5.7	617
114	EV PD-L1 is Correlated With Clinical Features and Contributes to T Cell Suppression in Pediatric Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2970-e2981.	1.8	15
115	Extracellular Vesicles in Renal Cell Carcinoma: Multifaceted Roles and Potential Applications Identified by Experimental and Computational Methods. <i>Frontiers in Oncology</i> , 2020, 10, 724.	1.3	18
116	Exosomal PD-L1: Roles in Tumor Progression and Immunotherapy. <i>Trends in Cancer</i> , 2020, 6, 550-558.	3.8	94
117	Exosomes as a Multicomponent Biomarker Platform in Cancer. <i>Trends in Cancer</i> , 2020, 6, 767-774.	3.8	175
118	Detection of Secretion of Exosomes from Individual Cell in Real-Time by Multifunctional Nanoelectrode-Nanopore Nanopipettes. <i>Chinese Journal of Analytical Chemistry</i> , 2020, 48, e20061-e20068.	0.9	3
119	Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093033.	1.4	25
120	Tumor-Derived Exosomes in Immunosuppression and Immunotherapy. <i>Journal of Immunology Research</i> , 2020, 2020, 1-11.	0.9	85
121	Multivalence-Actuated DNA Nanomachines Enable Bicolor Exosomal Phenotyping and PD-L1-Guided Therapy Monitoring. <i>Analytical Chemistry</i> , 2020, 92, 9877-9886.	3.2	38
122	Diagnostic and Therapeutic Applications of Exosomes in Cancer with a Special Focus on Head and Neck Squamous Cell Carcinoma (HNSCC). <i>International Journal of Molecular Sciences</i> , 2020, 21, 4344.	1.8	20
123	Soluble programmed death-ligand 1 rather than PD-L1 on tumor cells effectively predicts metastasis and prognosis in soft tissue sarcomas. <i>Scientific Reports</i> , 2020, 10, 9077.	1.6	36
124	Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28. <i>Frontiers in Oncology</i> , 2020, 10, 760.	1.3	33
125	Regulation of Cancer Immune Checkpoints. <i>Advances in Experimental Medicine and Biology</i> , 2020, , .	0.8	7
126	The function and clinical application of extracellular vesicles in innate immune regulation. <i>Cellular and Molecular Immunology</i> , 2020, 17, 323-334.	4.8	171
127	Immune Cell-Derived Exosomes in the Cancer-Immunity Cycle. <i>Trends in Cancer</i> , 2020, 6, 506-517.	3.8	95



#	ARTICLE	IF	CITATIONS
128	p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer. <i>Oncogene</i> , 2020, 39, 3939-3951.	2.6	70
129	Extracellular Vesicles and Chemotherapy Resistance in the AML Microenvironment. <i>Frontiers in Oncology</i> , 2020, 10, 90.	1.3	30
130	Nanosponges of circulating tumor-derived exosomes for breast cancer metastasis inhibition. <i>Biomaterials</i> , 2020, 242, 119932.	5.7	77
131	Tumor-derived extracellular vesicles: Regulators of tumor microenvironment and the enlightenment in tumor therapy. <i>Pharmacological Research</i> , 2020, 159, 105041.	3.1	16
132	Targeting extracellular vesicles-mediated hepatic inflammation as a therapeutic strategy in liver diseases. <i>Liver International</i> , 2020, 40, 2064-2073.	1.9	11
133	Perspectives in Manipulating EVs for Therapeutic Applications: Focus on Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4623.	1.8	19
134	Extracellular Vesicles in Cancer Metastasis: Potential as Therapeutic Targets and Materials. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4463.	1.8	50
135	PD-L1+ exosomes from bone marrow-derived cells of tumor-bearing mice inhibit antitumor immunity. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2402-2409.	4.8	23
136	On-Target Anti-TGF- $\beta$ 2 Therapies Are Not Succeeding in Clinical Cancer Treatments: What Are Remaining Challenges?. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 605.	1.8	127
137	Extracellular Vesicles Mediate B Cell Immune Response and Are a Potential Target for Cancer Therapy. <i>Cells</i> , 2020, 9, 1518.	1.8	35
138	Circulating miRNAs as Biomarkers in Aggressive B Cell Lymphomas. <i>Trends in Cancer</i> , 2020, 6, 910-923.	3.8	17
139	Mechanical strain induces phenotypic changes in breast cancer cells and promotes immunosuppression in the tumor microenvironment. <i>Laboratory Investigation</i> , 2020, 100, 1503-1516.	1.7	27
140	The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis. <i>Journal of Biomedical Science</i> , 2020, 27, 77.	2.6	89
141	The biology and function and biomedical applications of exosomes. <i>Science</i> , 2020, 367, .	6.0	4,742
142	Tracking the evolution of circulating exosomal PD-L1 to monitor melanoma patients. <i>Journal of Extracellular Vesicles</i> , 2020, 9, 1710899.	5.5	175
143	The importance of exosomal PDL1 in tumour immune evasion. <i>Nature Reviews Immunology</i> , 2020, 20, 209-215.	10.6	360
144	Unraveling the mechanisms that specify molecules for secretion in extracellular vesicles. <i>Methods</i> , 2020, 177, 15-26.	1.9	50
145	Homogeneous, Low-volume, Efficient, and Sensitive Quantitation of Circulating Exosomal PD-L1 for Cancer Diagnosis and Immunotherapy Response Prediction. <i>Angewandte Chemie</i> , 2020, 132, 4830-4835.	1.6	36

#	ARTICLE	IF	CITATIONS
146	Communication in tiny packages: Exosomes as means of tumor-stroma communication. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1873, 188340.	3.3	51
147	5-FU-Induced Upregulation of Exosomal PD-L1 Causes Immunosuppression in Advanced Gastric Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 492.	1.3	33
148	Learning from clinical trials of neoadjuvant checkpoint blockade. <i>Nature Medicine</i> , 2020, 26, 475-484.	15.2	107
149	Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source. <i>Drug Delivery</i> , 2020, 27, 585-598.	2.5	295
150	Emerging therapeutic targets for nasopharyngeal carcinoma: opportunities and challenges. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 545-558.	1.5	9
151	Tumor-Derived Extracellular Vesicles Impair CD171-Specific CD4+ CAR T Cell Efficacy. <i>Frontiers in Immunology</i> , 2020, 11, 531.	2.2	20
152	The Biogenesis, Biology, and Clinical Significance of Exosomal PD-L1 in Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 604.	2.2	51
153	Exosomal PD-L1 induces immunosuppressive nonclassical monocytes. <i>Neuro-Oncology</i> , 2020, 22, 901-902.	0.6	5
154	Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting. <i>Clinical Cancer Research</i> , 2020, 26, 2087-2095.	3.2	35
155	Immuno-Oncology Biomarkers for Personalized Immunotherapy in Breast Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 162.	1.8	21
156	Extracellular Vesicles and Tumor-Immune Escape: Biological Functions and Clinical Perspectives. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2286.	1.8	61
157	Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2367.	1.8	34
158	Top 100 most-cited articles on exosomes in the field of cancer: a bibliometric analysis and evidence mapping. <i>Clinical and Experimental Medicine</i> , 2021, 21, 181-194.	1.9	16
159	Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 1-9.	2.8	203
160	Chimeric antigen receptor $\alpha$ -modified macrophages trigger systemic anti-tumour immunity. <i>Journal of Pathology</i> , 2021, 253, 247-257.	2.1	42
161	Exosomes and extracellular vesicles as liquid biopsy biomarkers in diffuse large B-cell lymphoma: Current state of the art and unmet clinical needs. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 284-294.	1.1	12
162	Exosomes: A new horizon in modern medicine. <i>Life Sciences</i> , 2021, 264, 118623.	2.0	39
163	The cellular and molecular components involved in pre-metastatic niche formation in colorectal cancer liver metastasis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 389-399.	1.4	15

#	ARTICLE	IF	CITATIONS
164	Prognostic Value of Soluble Programmed Cell Death Ligand-1 (sPD-L1) in Various Cancers: A Meta-analysis. Targeted Oncology, 2021, 16, 13-26.	1.7	15
165	Tumor-derived exosomes in the PD-L1/PD-L1 axis: Significant regulators as well as promising clinical targets. Journal of Cellular Physiology, 2021, 236, 4138-4151.	2.0	17
166	Extracellular vesicles and oncogenic signaling. Molecular Oncology, 2021, 15, 3-26.	2.1	30
167	The role of hypoxia-inducible factor 1 in tumor immune evasion. Medicinal Research Reviews, 2021, 41, 1622-1643.	5.0	157
168	Tumor-derived extracellular vesicles containing microRNA-1290 promote immune escape of cancer cells through the Grhl2/ZEB1/PD-L1 axis in gastric cancer. Translational Research, 2021, 231, 102-112.	2.2	25
169	Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma. British Journal of Haematology, 2021, 192, 568-576.	1.2	19
170	Endometrial cell-derived small extracellular vesicle miR-100-5p promotes functions of trophoblast during embryo implantation. Molecular Therapy - Nucleic Acids, 2021, 23, 217-231.	2.3	30
171	Small extracellular vesicles containing miR-30a-3p attenuate the migration and invasion of hepatocellular carcinoma by targeting SNAP23 gene. Oncogene, 2021, 40, 233-245.	2.6	27
172	Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188463.	3.3	16
173	The potential role of tumor-derived exosomes in diagnosis, prognosis, and response to therapy in cancer. Expert Opinion on Biological Therapy, 2021, 21, 241-258.	1.4	29
174	Exosomes as mediators of immune regulation and immunotherapy in cancer. FEBS Journal, 2021, 288, 10-35.	2.2	110
175	Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors. Cellular and Molecular Life Sciences, 2021, 78, 867-887.	2.4	9
176	Reinvigorating exhausted CD8 <sup>+</sup> cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy. Medicinal Research Reviews, 2021, 41, 156-201.	5.0	56
177	Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer. Carcinogenesis, 2021, 42, 38-47.	1.3	46
178	Exploring the conformational dynamics of PD1 in complex with different ligands: What we can learn for designing novel PD1 signaling blockers?. Proteins: Structure, Function and Bioinformatics, 2021, 89, 141-148.	1.5	5
179	Role of Exosomes for Delivery of Chemotherapeutic Drugs. Critical Reviews in Therapeutic Drug Carrier Systems, 2021, 38, 53-97.	1.2	35
180	Proteomic Landscape of Exosomes Reveals the Functional Contributions of CD151 in Triple-Negative Breast Cancer. Molecular and Cellular Proteomics, 2021, 20, 100121.	2.5	39
181	<i>YKT6</i> , as a potential predictor of prognosis and immunotherapy response for oral squamous cell carcinoma, is related to cell invasion, metastasis, and CD8 <sup>+</sup> T cell infiltration. Oncoimmunology, 2021, 10, 1938890.	2.1	46

#	ARTICLE	IF	CITATIONS
182	Exosomal Long Non-Coding RNA: Interaction Between Cancer Cells and Non-Cancer Cells. <i>Frontiers in Oncology</i> , 2020, 10, 617837.	1.3	15
183	Extracellular Vesicles in Chemoresistance. <i>Sub-Cellular Biochemistry</i> , 2021, 97, 211-245.	1.0	3
184	Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1. , 2021, 9, e001698.		78
185	B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1910-1922.	1.4	9
186	PD-L1 cellular nanovesicles carrying rapamycin inhibit alloimmune responses in transplantation. <i>Biomaterials Science</i> , 2021, 9, 1246-1255.	2.6	9
187	Doxorubicin and PD-L1 siRNA co-delivery with stem cell membrane-coated polydopamine nanoparticles for the targeted chemoimmunotherapy of PCa bone metastases. <i>Nanoscale</i> , 2021, 13, 8998-9008.	2.8	61
188	PD-L1 Promotes Retraction Fiber Formation and Determines Persistent Cell Migration by Altering Integrin $\beta$ 4 Dynamics. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
189	Autophagy Blockade Limits HER2+ Breast Cancer Tumorigenesis by Perturbing HER2 Trafficking and Promoting Release Via Small Extracellular Vesicles. <i>Developmental Cell</i> , 2021, 56, 341-355.e5.	3.1	25
190	Immune Deregulation in Sepsis and Septic Shock: Reversing Immune Paralysis by Targeting PD-1/PD-L1 Pathway. <i>Frontiers in Immunology</i> , 2020, 11, 624279.	2.2	58
191	WJMSCâ€derived small extracellular vesicle enhance T cell suppression through PDâ€L1. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12067.	5.5	39
192	Phenotypic and Proteomic Analysis Identifies Hallmarks of Blood Circulating Extracellular Vesicles in NSCLC Responders to Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 585.	1.7	25
193	Tracing Tumorâ€Derived Exosomal PDâ€L1 by Dualâ€Aptamer Activated Proximityâ€Induced Droplet Digital PCR. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 7582-7586.	7.2	117
194	Metabolic Factors Affecting Tumor Immunogenicity: What Is Happening at the Cellular Level?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2142.	1.8	6
195	miR-224-5p Contained in Urinary Extracellular Vesicles Regulates PD-L1 Expression by Inhibiting Cyclin D1 in Renal Cell Carcinoma Cells. <i>Cancers</i> , 2021, 13, 618.	1.7	20
196	Reprogramming the Tumor Microenvironment through Secondâ€Nearâ€Infraredâ€Window Photothermal Genome Editing of <i>PDâ€L1</i> Mediated by Supramolecular Gold Nanorods for Enhanced Cancer Immunotherapy. <i>Advanced Materials</i> , 2021, 33, e2006003.	11.1	131
197	WHSC1/NSD2 regulates immune infiltration in prostate cancer. , 2021, 9, e001374.		17
198	Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities. <i>Frontiers in Oncology</i> , 2020, 10, 626129.	1.3	48
199	Tracing Tumorâ€Derived Exosomal PDâ€L1 by Dualâ€Aptamer Activated Proximityâ€Induced Droplet Digital PCR. <i>Angewandte Chemie</i> , 2021, 133, 7660-7664.	1.6	5

#	ARTICLE	IF	CITATIONS
200	Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review. <i>Experimental Hematology and Oncology</i> , 2021, 10, 13.	2.0	16
201	Integrin Regulation in Immunological and Cancerous Cells and Exosomes. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2193.	1.8	26
202	Challenges and advances in clinical applications of mesenchymal stromal cells. <i>Journal of Hematology and Oncology</i> , 2021, 14, 24.	6.9	247
203	Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy. <i>Journal of Immunology Research</i> , 2021, 2021, 1-18.	0.9	29
204	Exosomes as Pleiotropic Players in Pancreatic Cancer. <i>Biomedicines</i> , 2021, 9, 275.	1.4	14
205	Charged Particle and Conventional Radiotherapy: Current Implications as Partner for Immunotherapy. <i>Cancers</i> , 2021, 13, 1468.	1.7	24
206	Could Extracellular Vesicles Contribute to Generation or Awakening of "Sleepy" Metastatic Niches?. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 625221.	1.8	11
207	Immunosuppressive Cell Subsets and Factors in Myeloid Leukemias. <i>Cancers</i> , 2021, 13, 1203.	1.7	16
208	Cell-Based Delivery Systems: Emerging Carriers for Immunotherapy. <i>Advanced Functional Materials</i> , 2021, 31, 2100088.	7.8	60
209	Circular RNA CHST15 Sponges miR-155-5p and miR-194-5p to Promote the Immune Escape of Lung Cancer Cells Mediated by PD-L1. <i>Frontiers in Oncology</i> , 2021, 11, 595609.	1.3	24
210	The role of exosomes in tumour immunity under radiotherapy: eliciting abscopal effects?. <i>Biomarker Research</i> , 2021, 9, 22.	2.8	13
211	Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti-PD-1 Therapy Efficacy. <i>Cancer Immunology Research</i> , 2021, 9, 568-582.	1.6	30
212	HuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer. <i>Oncogene</i> , 2021, 40, 2230-2242.	2.6	26
213	Underlying mechanisms and drug intervention strategies for the tumour microenvironment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 97.	3.5	22
214	Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment. <i>Clinical Cancer Research</i> , 2021, 27, 3253-3264.	3.2	26
215	S1 nuclease digestion-based rational truncation of PD-L1 aptamer and establishment of a signal dual amplification aptasensor. <i>Sensors and Actuators B: Chemical</i> , 2021, 331, 129442.	4.0	20
216	Small Extracellular Vesicles: A Novel Avenue for Cancer Management. <i>Frontiers in Oncology</i> , 2021, 11, 638357.	1.3	34
217	The Role of Tumor-Derived Exosomes in the Abscopal Effect and Immunotherapy. <i>Life</i> , 2021, 11, 381.	1.1	8

#	ARTICLE	IF	CITATIONS
218	Secretion rates and protein composition of extracellular vesicles released by cancer-associated fibroblasts after radiation. <i>Journal of Radiation Research</i> , 2021, 62, 401-413.	0.8	15
219	Exosomes: Powerful weapon for cancer nano-immunoengineering. <i>Biochemical Pharmacology</i> , 2021, 186, 114487.	2.0	20
220	Urinary extracellular vesicles: a rising star in bladder cancer management. <i>Translational Andrology and Urology</i> , 2021, 10, 1878-1889.	0.6	12
221	Post-translational regulations of PD-L1 and PD-1: Mechanisms and opportunities for combined immunotherapy. <i>Seminars in Cancer Biology</i> , 2022, 85, 246-252.	4.3	38
222	Towards microfluidic-based exosome isolation and detection for tumor therapy. <i>Nano Today</i> , 2021, 37, 101066.	6.2	112
223	Thyroid hormone synthesis continues despite biallelic thyroglobulin mutation with cell death. <i>JCI Insight</i> , 2021, 6, .	2.3	6
224	Exosomes in Liquid Biopsy: The Nanometric World in the Pursuit of Precision Oncology. <i>Cancers</i> , 2021, 13, 2147.	1.7	35
225	Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer. <i>Scientific Reports</i> , 2021, 11, 7830.	1.6	50
226	Professional killers: The role of extracellular vesicles in the reciprocal interactions between natural killer, CD8+ cytotoxic T cells and tumour cells. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12075.	5.5	33
227	Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy. <i>Journal of Controlled Release</i> , 2021, 332, 109-126.	4.8	33
228	Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients. <i>Frontiers in Immunology</i> , 2021, 12, 665133.	2.2	41
229	Sulindac Modulates the Response of Proficient MMR Colorectal Cancer to Anti-PD-L1 Immunotherapy. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1295-1304.	1.9	2
230	Co-Isolation of Cytokines and Exosomes: Implications for Immunomodulation Studies. <i>Frontiers in Immunology</i> , 2021, 12, 638111.	2.2	13
231	Erythrocyte-mediated systemic immunotherapy. <i>Nature Biomedical Engineering</i> , 2021, 5, 385-386.	11.6	1
232	The role of exosomal PD-L1 in tumor immunotherapy. <i>Translational Oncology</i> , 2021, 14, 101047.	1.7	31
233	Potential of peptide-engineered exosomes with overexpressed miR-92b-3p in anti-angiogenic therapy of ovarian cancer. <i>Clinical and Translational Medicine</i> , 2021, 11, e425.	1.7	28
234	Engineering of Extracellular Vesicles Based on Payload Changes for Tissue Regeneration. <i>Tissue Engineering and Regenerative Medicine</i> , 2021, 18, 485-497.	1.6	9
235	GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma. <i>Molecular Cancer</i> , 2021, 20, 80.	7.9	17

#	ARTICLE	IF	CITATIONS
236	Programmed Death-Ligand 1 as a Regulator of Tumor Progression and Metastasis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5383.	1.8	10
237	Local oncolytic adenovirotherapy produces an abscopal effect via tumor-derived extracellular vesicles. <i>Molecular Therapy</i> , 2021, 29, 2920-2930.	3.7	14
238	Advances in Biological Function and Clinical Application of Small Extracellular Vesicle Membrane Proteins. <i>Frontiers in Oncology</i> , 2021, 11, 675940.	1.3	19
239	Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5158.	1.8	3
240	Roles of exosomes in cancer chemotherapy resistance, progression, metastasis and immunity, and their clinical applications (Review). <i>International Journal of Oncology</i> , 2021, 59, .	1.4	20
242	Diagnostic and prognostic potential of the proteomic profiling of serum-derived extracellular vesicles in prostate cancer. <i>Cell Death and Disease</i> , 2021, 12, 636.	2.7	20
243	Glyoxalase-1-Dependent Methylglyoxal Depletion Sustains PD-L1 Expression in Metastatic Prostate Cancer Cells: A Novel Mechanism in Cancer Immunosurveillance Escape and a Potential Novel Target to Overcome PD-L1 Blockade Resistance. <i>Cancers</i> , 2021, 13, 2965.	1.7	14
244	The roles of tumor-derived exosomes in altered differentiation, maturation and function of dendritic cells. <i>Molecular Cancer</i> , 2021, 20, 83.	7.9	47
245	Plasma Extracellular Vesicles Enhance HIV-1 Infection of Activated CD4+ T Cells and Promote the Activation of Latently Infected J-Lat10.6 Cells via miR-139-5p Transfer. <i>Frontiers in Immunology</i> , 2021, 12, 697604.	2.2	14
246	PD-L1 detection on circulating tumor-derived extracellular vesicles (T-EVs) from patients with lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2441-2451.	1.3	19
247	GPC5 suppresses lung cancer progression and metastasis via intracellular CTDSF1/AhR/ARNT signaling axis and extracellular exosome secretion. <i>Oncogene</i> , 2021, 40, 4307-4323.	2.6	14
248	Extracellular vesicle-mediated and particle-mediated communication shapes innate and adaptive immune responses. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	47
249	Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer. <i>Oncogene</i> , 2021, 40, 4992-5001.	2.6	68
250	Complement factor H protects tumor cell-derived exosomes from complement-dependent lysis and phagocytosis. <i>PLoS ONE</i> , 2021, 16, e0252577.	1.1	10
251	A Checkpoint-Regulatable Immune Niche Created by Injectable Hydrogel for Tumor Therapy. <i>Advanced Functional Materials</i> , 2021, 31, 2104630.	7.8	65
252	No small matter: emerging roles for exosomal miRNAs in the immune system. <i>FEBS Journal</i> , 2022, 289, 4021-4037.	2.2	10
253	Orexin A Suppresses the Expression of Exosomal PD-L1 in Colon Cancer and Promotes T Cell Activity by Inhibiting JAK2/STAT3 Signaling Pathway. <i>Digestive Diseases and Sciences</i> , 2022, 67, 2173-2181.	1.1	10
254	Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 184.	3.5	204

#	ARTICLE	IF	CITATIONS
255	Exosomes in the lung cancer microenvironment: biological functions and potential use as clinical biomarkers. <i>Cancer Cell International</i> , 2021, 21, 333.	1.8	10
256	Tumor microenvironment-based drug discovery: a novel insight into bladder cancer immunotherapy. <i>Chinese Medical Journal</i> , 2021, 134, 1885-1886.	0.9	1
257	Prognostic prospect of soluble programmed cell death ligand-1 in cancer management. <i>Acta Biochimica Et Biophysica Sinica</i> , 2021, 53, 961-978.	0.9	4
258	Exploring interactions between extracellular vesicles and cells for innovative drug delivery system design. <i>Advanced Drug Delivery Reviews</i> , 2021, 173, 252-278.	6.6	55
259	Extracellular Vesicles in Advanced Prostate Cancer: Tools to Predict and Thwart Therapeutic Resistance. <i>Cancers</i> , 2021, 13, 3791.	1.7	5
260	PDL1 <sup>+</sup> positive exosomes suppress antitumor immunity by inducing tumor-specific CD8 <sup>+</sup> T cell exhaustion during metastasis. <i>Cancer Science</i> , 2021, 112, 3437-3454.	1.7	33
261	Emerging Role of Extracellular Vesicles in Prostate Cancer. <i>Endocrinology</i> , 2021, 162, .	1.4	5
262	Coupling Aptamer-based Protein Tagging with Metabolic Glycan Labeling for In Situ Visualization and Biological Function Study of Exosomal Protein-specific Glycosylation. <i>Angewandte Chemie</i> , 2021, 133, 18259-18263.	1.6	9
263	Circulating PD-L1 is associated with T cell infiltration and predicts prognosis in patients with CRLM following hepatic resection. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 661-674.	2.0	8
264	The role of extracellular vesicles in the physiological and pathological regulation of the blood-brain barrier. <i>FASEB BioAdvances</i> , 2021, 3, 665-675.	1.3	41
265	Inhibition of xCT suppresses the efficacy of anti-PD-1/L1 melanoma treatment through exosomal PD-L1-induced macrophage M2 polarization. <i>Molecular Therapy</i> , 2021, 29, 2321-2334.	3.7	48
266	Engineered extracellular vesicles for concurrent Anti-PDL1 immunotherapy and chemotherapy. <i>Bioactive Materials</i> , 2022, 9, 251-265.	8.6	30
267	Extracellular Vesicles as an Advanced Delivery Biomaterial for Precision Cancer Immunotherapy. <i>Advanced Healthcare Materials</i> , 2022, 11, e2100650.	3.9	27
268	Exosomes as New Biomarkers and Drug Delivery Tools for the Prevention and Treatment of Various Diseases: Current Perspectives. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7763.	1.8	22
269	The multifaceted involvement of exosomes in tumor progression: Induction and inhibition. <i>MedComm</i> , 2021, 2, 297-314.	3.1	10
270	Characterizing the Heterogeneity of Small Extracellular Vesicle Populations in Multiple Cancer Types via an Ultrasensitive Chip. <i>ACS Sensors</i> , 2021, 6, 3182-3194.	4.0	22
271	The role of exosomes in lung cancer metastasis and clinical applications: an updated review. <i>Journal of Translational Medicine</i> , 2021, 19, 312.	1.8	32
272	Coupling Aptamer-based Protein Tagging with Metabolic Glycan Labeling for In Situ Visualization and Biological Function Study of Exosomal Protein-specific Glycosylation. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 18111-18115.	7.2	66



#	ARTICLE	IF	CITATIONS
273	A Small Vimentin-Binding Molecule Blocks Cancer Exosome Release and Reduces Cancer Cell Mobility. <i>Frontiers in Pharmacology</i> , 2021, 12, 627394.	1.6	13
274	Oncogene-regulated release of extracellular vesicles. <i>Developmental Cell</i> , 2021, 56, 1989-2006.e6.	3.1	37
275	Nipping disease in the bud: nSMase2 inhibitors as therapeutics in extracellular vesicle-mediated diseases. <i>Drug Discovery Today</i> , 2021, 26, 1656-1668.	3.2	21
276	THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy. , 2021, 9, e002443.		16
277	Tumor-Derived Extracellular Vesicles: Their Role in Immune Cells and Immunotherapy. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 5395-5409.	3.3	25
278	LncRNA nuclear-enriched abundant transcript 1 shuttled by prostate cancer cells-secreted exosomes initiates osteoblastic phenotypes in the bone metastatic microenvironment via miR-205a-5p/runt-related transcription factor 2/splicing factor proline- and glutamine-rich/polypyrimidine tract-binding protein 2 axis. <i>Clinical and Translational Medicine</i> , 2021, 11, e493.	1.7	35
279	Exosomes and prostate cancer management. <i>Seminars in Cancer Biology</i> , 2022, 86, 101-111.	4.3	11
280	Tumor-derived exosomes: Nanovesicles made by cancer cells to promote cancer metastasis. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 2136-2149.	5.7	35
281	Mesenchymal Stem Cell-Derived Exosomes: Applications in Regenerative Medicine. <i>Cells</i> , 2021, 10, 1959.	1.8	171
282	PD-L1 degradation is regulated by electrostatic membrane association of its cytoplasmic domain. <i>Nature Communications</i> , 2021, 12, 5106.	5.8	38
283	Methylseleninic acid overcomes programmed death-ligand 1-mediated resistance of prostate cancer and lung cancer. <i>Molecular Carcinogenesis</i> , 2021, 60, 746-757.	1.3	9
284	Tumor-Secreted Extracellular Vesicles Regulate T-Cell Costimulation and Can Be Manipulated To Induce Tumor-Specific T-Cell Responses. <i>Gastroenterology</i> , 2021, 161, 560-574.e11.	0.6	47
285	A Novel Microfluidic Chip for Fast, Sensitive Quantification of Plasma Extracellular Vesicles as Biomarkers in Patients With Osteosarcoma. <i>Frontiers in Oncology</i> , 2021, 11, 709255.	1.3	6
286	Exosomal circEIF3K from cancer-associated fibroblast promotes colorectal cancer (CRC) progression via miR-214/PD-L1 axis. <i>BMC Cancer</i> , 2021, 21, 933.	1.1	62
287	Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy. <i>Cancers</i> , 2021, 13, 4280.	1.7	16
288	Intercellular communication through extracellular vesicles in cancer and evolutionary biology. <i>Progress in Biophysics and Molecular Biology</i> , 2021, 165, 80-87.	1.4	6
289	PD-1/PD-L1 immune checkpoints: Tumor vs atherosclerotic progression. <i>Clinica Chimica Acta</i> , 2021, 519, 70-75.	0.5	8
290	PD-L1 expression as a predictive biomarker for immune checkpoint inhibitors: between a dream and a nightmare. <i>Immunotherapy</i> , 2021, 13, 1053-1065.	1.0	16

#	ARTICLE	IF	CITATIONS
291	PD-L1 Protein Expression and Gene Amplification Correlate with the Clinicopathological Characteristics and Prognosis of Lung Squamous Cell Carcinoma. <i>Cancer Management and Research</i> , 2021, Volume 13, 6365-6375.	0.9	2
292	Identification of the Immune-Related Genes in Tumor Microenvironment That Associated With the Recurrence of Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 723721.	1.8	6
293	Non-cytoplasmic PD-L1: An atypical target for cancer. <i>Pharmacological Research</i> , 2021, 170, 105741.	3.1	19
294	Endoglin-Aptamer-Functionalized Liposome-Equipped PD-1-Silenced T Cells Enhance Antitumoral Immunotherapeutic Effects. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 6017-6034.	3.3	10
295	Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 651634.	2.2	47
296	Tumor-Derived Exosomes: Hidden Players in PD-1/PD-L1 Resistance. <i>Cancers</i> , 2021, 13, 4537.	1.7	20
297	The mantle exosome proteins of <i>Hyriopsis cumingii</i> participate in shell and nacre color formation. <i>Comparative Biochemistry and Physiology Part D: Genomics and Proteomics</i> , 2021, 39, 100844.	0.4	4
298	Exosomes and organ-specific metastasis. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 22, 133-147.	1.8	28
299	The effects of tumor-derived exosomes on T cell function and efficacy of cancer immunotherapy. <i>Immunomedicine</i> , 2021, 1, e1029.	0.7	3
300	Exosomes and extracellular vesicles: Rethinking the essential values in cancer biology. <i>Seminars in Cancer Biology</i> , 2021, 74, 79-91.	4.3	65
301	Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming. <i>Cell Metabolism</i> , 2021, 33, 2040-2058.e10.	7.2	200
302	Extracellular vesicles in the tumor immune microenvironment. <i>Cancer Letters</i> , 2021, 516, 48-56.	3.2	25
303	Repurposing macitentan with nanoparticle modulates tumor microenvironment to potentiate immune checkpoint blockade. <i>Biomaterials</i> , 2021, 276, 121058.	5.7	13
304	Liquid Biopsy Biomarkers for Immunotherapy in Non-Small Cell Lung Carcinoma: Lessons Learned and the Road Ahead. <i>Journal of Personalized Medicine</i> , 2021, 11, 971.	1.1	5
305	Coadministration of iRGD peptide with ROS-sensitive nanoparticles co-delivering siFGL1 and siPD-L1 enhanced tumor immunotherapy. <i>Acta Biomaterialia</i> , 2021, 136, 473-484.	4.1	26
306	Exosomes: A Forthcoming Era of Breast Cancer Therapeutics. <i>Cancers</i> , 2021, 13, 4672.	1.7	18
307	Nanoplasmonic Sandwich Immunoassay for Tumor-Derived Exosome Detection and Exosomal PD-L1 Profiling. <i>ACS Sensors</i> , 2021, 6, 3308-3319.	4.0	35
308	Exosomes-mediated tumor treatment: One body plays multiple roles. <i>Asian Journal of Pharmaceutical Sciences</i> , 2022, 17, 385-400.	4.3	11

#	ARTICLE	IF	CITATIONS
309	Interaction Between Modern Radiotherapy and Immunotherapy for Metastatic Prostate Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 744679.	1.3	7
310	T lymphocyte membrane-decorated epigenetic nanoinducer of interferons for cancer immunotherapy. <i>Nature Nanotechnology</i> , 2021, 16, 1271-1280.	15.6	75
311	A nanounit strategy reverses immune suppression of exosomal PD-L1 and is associated with enhanced ferroptosis. <i>Nature Communications</i> , 2021, 12, 5733.	5.8	95
312	Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 716844.	1.3	12
313	The biology, function, and applications of exosomes in cancer. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 2783-2797.	5.7	209
314	The generation of PD-L1 and PD-L2 in cancer cells: From nuclear chromatin reorganization to extracellular presentation. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 1041-1053.	5.7	27
315	The Key Role of Exosomes on the Pre-metastatic Niche Formation in Tumors. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 703640.	1.6	38
316	Harnessing EV communication to restore antitumor immunity. <i>Advanced Drug Delivery Reviews</i> , 2021, 176, 113838.	6.6	7
317	PD-L1 regulation revisited: impact on immunotherapeutic strategies. <i>Trends in Molecular Medicine</i> , 2021, 27, 868-881.	3.5	30
318	Extracellular and nuclear PD-L1 in modulating cancer immunotherapy. <i>Trends in Cancer</i> , 2021, 7, 837-846.	3.8	45
320	Landscape of extracellular vesicles in the tumour microenvironment: Interactions with stromal cells and with non-cell components, and impacts on metabolic reprogramming, horizontal transfer of neoplastic traits, and the emergence of therapeutic resistance. <i>Seminars in Cancer Biology</i> , 2021, 74, 24-44.	4.3	34
321	Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 99, 102242.	3.4	13
322	Tumor-derived microparticles promote the progression of triple-negative breast cancer via PD-L1-associated immune suppression. <i>Cancer Letters</i> , 2021, 523, 43-56.	3.2	23
323	Harnessing the therapeutic potential of extracellular vesicles for cancer treatment. <i>Seminars in Cancer Biology</i> , 2021, 74, 92-104.	4.3	9
324	The Immunomodulation Potential of Exosomes in Tumor Microenvironment. <i>Journal of Immunology Research</i> , 2021, 2021, 1-11.	0.9	15
325	Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments. , 2021, 9, e003148.		18
326	Bispecific antibody CD73xEpCAM selectively inhibits the adenosine-mediated immunosuppressive activity of carcinoma-derived extracellular vesicles. <i>Cancer Letters</i> , 2021, 521, 109-118.	3.2	12
327	New insights into exosome mediated tumor-immune escape: Clinical perspectives and therapeutic strategies. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188624.	3.3	29

#	ARTICLE	IF	CITATIONS
328	Development of natural products for anti-PD-1/PD-L1 immunotherapy against cancer. <i>Journal of Ethnopharmacology</i> , 2021, 281, 114370.	2.0	25
329	Prognostic features of the tumour microenvironment in oesophageal adenocarcinoma. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188598.	3.3	8
330	Correlation of ARNTL2 with Immune Infiltration and Its Role as a Potential Prognostic Biomarker in Lung Adenocarcinoma. <i>Clinical Complementary Medicine and Pharmacology</i> , 2021, 1, 100005.	0.9	4
331	Breast cancer-derived DAMPs enhance cell invasion and metastasis, while nucleic acid scavengers mitigate these effects. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 26, 1-10.	2.3	11
332	Emerging role of exosomes and exosomal microRNA in cancer: pathophysiology and clinical potential. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 637-648.	1.2	26
333	An Immunocapture-Based Assay for Detecting Multiple Antigens in Melanoma-Derived Extracellular Vesicles. <i>Methods in Molecular Biology</i> , 2021, 2265, 323-344.	0.4	9
334	EV PD-L1 Contributes to Immunosuppressive CD8 <sup>+</sup> T Cells in Peripheral Blood of Pediatric Wilms Tumor. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110412.	0.8	3
336	Exosomes in Immune Regulation. <i>Non-coding RNA</i> , 2021, 7, 4.	1.3	23
337	Isolation and Characterization of Extracellular Vesicles from Cell Culture Conditioned Medium for Immunological Studies. <i>Current Protocols in Immunology</i> , 2020, 129, e96.	3.6	8
338	Checkpoints Under Traffic Control: From and to Organelles. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 431-453.	0.8	8
339	Small Molecular Immune Modulators as Anticancer Agents. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 547-618.	0.8	6
340	Actin remodeling and vesicular trafficking at the tumor cell side of the immunological synapse direct evasion from cytotoxic lymphocytes. <i>International Review of Cell and Molecular Biology</i> , 2020, 356, 99-130.	1.6	9
341	Matrine reduces the secretion of exosomal circSLC7A6 from cancer-associated fibroblast to inhibit tumorigenesis of colorectal cancer by regulating CXCR5. <i>Biochemical and Biophysical Research Communications</i> , 2020, 527, 638-645.	1.0	41
342	miR-20a-5p is enriched in hypoxia-derived tubular exosomes and protects against acute tubular injury. <i>Clinical Science</i> , 2020, 134, 2223-2234.	1.8	32
344	Senescent T cells within suppressive tumor microenvironments: emerging target for tumor immunotherapy. <i>Journal of Clinical Investigation</i> , 2020, 130, 1073-1083.	3.9	53
345	The role of extracellular vesicles in prostate cancer with clinical applications. <i>Endocrine-Related Cancer</i> , 2020, 27, R133-R144.	1.6	12
346	A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy. , 2020, 3, 252-275.		18
347	The Role of Tumor-Derived Vesicles in the Regulation of Antitumor Immunity. <i>Acta Naturae</i> , 2019, 11, 33-41.	1.7	18

#	ARTICLE	IF	CITATIONS
348	Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade. <i>Frontiers in Immunology</i> , 2020, 11, 339.	2.2	77
349	Exosomes: Their Role in Pathogenesis, Diagnosis and Treatment of Diseases. <i>Cancers</i> , 2021, 13, 84.	1.7	36
350	Extracellular Vesicles for Cancer Therapy: Impact of Host Immune Response. <i>Cells</i> , 2020, 9, 224.	1.8	10
352	Soluble PD-L1 generated by endogenous retroelement exaptation is a receptor antagonist. <i>ELife</i> , 2019, 8, .	2.8	44
353	The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy. <i>ELife</i> , 2020, 9, .	2.8	168
354	The Emerging Role of Exosomes as Cancer Theranostics. <i>Nanotechnology in the Life Sciences</i> , 2021, , 297-315.	0.4	1
355	Emerging role of tumor-derived extracellular vesicles in T cell suppression and dysfunction in the tumor microenvironment. , 2021, 9, e003217.		29
356	Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3653-3664.	1.2	19
357	Neddylation of Coro1a determines the fate of multivesicular bodies and biogenesis of extracellular vesicles. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12153.	5.5	25
358	Effects of Tumor-Derived Exosome Programmed Death Ligand 1 on Tumor Immunity and Clinical Applications. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 760211.	1.8	9
360	Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. <i>Cell</i> , 2021, 184, 5309-5337.	13.5	588
361	Application of extracellular vesicles in the diagnosis and treatment of prostate cancer: implications for clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 167, 103495.	2.0	11
362	Non-immune Cell Components in the Gastrointestinal Tumor Microenvironment Influencing Tumor Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 729941.	1.8	4
363	Crosstalk Between the Tumor Microenvironment and Cancer Cells: A Promising Predictive Biomarker for Immune Checkpoint Inhibitors. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 738373.	1.8	15
364	Recent advances in primary resistance mechanisms against immune checkpoint inhibitors. <i>Current Opinion in Oncology</i> , 2022, 34, 95-106.	1.1	9
365	Extracellular vesicles: mediators of intercellular communication in tissue injury and disease. <i>Cell Communication and Signaling</i> , 2021, 19, 104.	2.7	78
366	Serological assessment of collagen fragments and tumor fibrosis may guide immune checkpoint inhibitor therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 326.	3.5	19
367	Integrins in exosomes. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2019, 30, 596-602.	0.1	0

#	ARTICLE	IF	CITATIONS
369	Extracellular Vesicles and Their Roles in Cancer Progression. <i>Methods in Molecular Biology</i> , 2021, 2174, 143-170.	0.4	82
370	Immunometabolism and Its Potential to Improve the Current Limitations of Immunotherapy. <i>Methods in Molecular Biology</i> , 2020, 2184, 233-263.	0.4	1
371	Personalized Immuno-Oncology. , 2021, , 479-508.		2
372	Universal extracellular vesicles and PD-L1+ extracellular vesicles detected by single molecule array technology as circulating biomarkers for diffuse large B cell lymphoma. <i>OncolImmunology</i> , 2021, 10, 1995166.	2.1	12
373	Nucleic-Acid Scavengers Mitigate Breast Cancer Induced Inflammation, Invasion, and Metastasis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
374	The roles of exosomal immune checkpoint proteins in tumors. <i>Military Medical Research</i> , 2021, 8, 56.	1.9	12
375	Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1549-1567.	2.0	20
376	CD73-positive extracellular vesicles promote glioblastoma immunosuppression by inhibiting T-cell clonal expansion. <i>Cell Death and Disease</i> , 2021, 12, 1065.	2.7	30
379	BMAL1 induces colorectal cancer metastasis by stimulating exosome secretion. <i>Molecular Biology Reports</i> , 2022, 49, 373-384.	1.0	11
380	Clinical significance of circulating exosomal PD-L1 and soluble PD-L1 in extranodal NK/T-cell lymphoma, nasal-type. <i>American Journal of Cancer Research</i> , 2020, 10, 4498-4512.	1.4	6
381	Extracellular vesicles in Inter-Kingdom communication in gastrointestinal cancer. <i>American Journal of Cancer Research</i> , 2021, 11, 1087-1103.	1.4	2
382	Disposable amperometric immunosensor with a dual monomers-based bioconjugate for granzyme B detection in blood and cancer progress monitoring of patients. <i>Biosensors and Bioelectronics</i> , 2022, 198, 113846.	5.3	10
384	Tumor-derived exosomal PD-L1 in progression of cancer and immunotherapy. <i>Journal of Cellular Physiology</i> , 2022, 237, 1648-1660.	2.0	10
385	The Role of Exosomes and Their Applications in Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12204.	1.8	64
386	Tumor-Associated Exosomes: A Potential Therapeutic Target for Restoring Anti-Tumor T Cell Responses in Human Tumor Microenvironments. <i>Cells</i> , 2021, 10, 3155.	1.8	11
387	GOLM1 exacerbates CD8+ T cell suppression in hepatocellular carcinoma by promoting exosomal PD-L1 transport into tumor-associated macrophages. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 397.	7.1	58
388	Validation of PD-L1 dynamic expression on extracellular vesicles as a predictor of response to immune-checkpoint inhibitors and survival in non-small cell lung cancer patients. , 2021, 9, A25-A26.		0
389	Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave. <i>Biomedicines</i> , 2021, 9, 1702.	1.4	11

#	ARTICLE	IF	CITATIONS
390	The Importance of Exosomal PD-L1 in Cancer Progression and Its Potential as a Therapeutic Target. <i>Cells</i> , 2021, 10, 3247.	1.8	24
391	Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation. <i>Journal of Immunology Research</i> , 2021, 2021, 1-18.	0.9	21
392	Emerging role of exosomes as biomarkers in cancer treatment and diagnosis. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103565.	2.0	49
393	Extracellular Vesicles and Glycosylation. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1325, 137-149.	0.8	6
394	Cancer-specific type-I interferon receptor signaling promotes cancer stemness and effector CD8+ T-cell exhaustion. <i>Oncot Immunology</i> , 2021, 10, 1997385.	2.1	23
395	The Role of Small Extracellular Vesicles in the Progression of Colorectal Cancer and Its Clinical Applications. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1379.	1.8	8
396	Tumor-Derived Exosomes in Tumor-Induced Immune Suppression. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1461.	1.8	28
397	Exosomes Regulate NLRP3 Inflammasome in Diseases. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 802509.	1.8	11
398	Phototheranostic Metal-Phenolic Networks with Antiexosomal PD-L1 Enhanced Ferroptosis for Synergistic Immunotherapy. <i>Journal of the American Chemical Society</i> , 2022, 144, 787-797.	6.6	142
399	Exosomes in the hypoxic TME: from release, uptake and biofunctions to clinical applications. <i>Molecular Cancer</i> , 2022, 21, 19.	7.9	63
400	Enhancing the anti-leukemia immunity of acute lymphocytic leukemia-derived exosome-based vaccine by downregulation of PD-L1 expression. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2197-2212.	2.0	9
402	Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis. <i>Future Oncology</i> , 2022, 18, 261-273.	1.1	10
403	ICAM-1-mediated adhesion is a prerequisite for exosome-induced T cell suppression. <i>Developmental Cell</i> , 2022, 57, 329-343.e7.	3.1	42
404	Extracellular Vesicles as Mediators of Therapy Resistance in the Breast Cancer Microenvironment. <i>Biomolecules</i> , 2022, 12, 132.	1.8	7
405	Enigmatic role of exosomes in breast cancer progression and therapy. <i>Life Sciences</i> , 2022, 289, 120210.	2.0	16
406	Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2. <i>Nature Communications</i> , 2022, 13, 405.	5.8	92
407	Extracellular vesicle PD-L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies. <i>Cell Communication and Signaling</i> , 2022, 20, 14.	2.7	23
408	PD-L1 in circulating exosomes of Merkel cell carcinoma. <i>Experimental Dermatology</i> , 2022, 31, 869-877.	1.4	6

#	ARTICLE	IF	CITATIONS
409	Extracellular vesicles containing PD-L1 contribute to CD8+ T-cell immune suppression and predict poor outcomes in small cell lung cancer. <i>Clinical and Experimental Immunology</i> , 2022, 207, 307-317.	1.1	21
410	A prospective phase II clinical trial identifying the optimal regimen for carboplatin plus standard backbone of anthracycline and taxane-based chemotherapy in triple negative breast cancer. <i>Medical Oncology</i> , 2022, 39, 49.	1.2	5
411	Myricetin inhibits interferon- $\beta$ -induced PD-L1 and IDO1 expression in lung cancer cells. <i>Biochemical Pharmacology</i> , 2022, 197, 114940.	2.0	20
412	The interweaving relationship between extracellular vesicles and T cells in cancer. <i>Cancer Letters</i> , 2022, 530, 1-7.	3.2	11
413	Tumor-derived exosomes: immune properties and clinical application in lung cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 102-113.	0.9	5
414	Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1. <i>Theranostics</i> , 2022, 12, 1971-1987.	4.6	30
415	Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 287-305.	12.5	155
416	4-1BBL-containing leukemic extracellular vesicles promote immunosuppressive effector regulatory T cells. <i>Blood Advances</i> , 2022, 6, 1879-1894.	2.5	13
417	PD-L1 signaling in reactive astrocytes counteracts neuroinflammation and ameliorates neuronal damage after traumatic brain injury. <i>Journal of Neuroinflammation</i> , 2022, 19, 43.	3.1	21
418	The mouse resource at National Resource Center for Mutant Mice. <i>Mammalian Genome</i> , 2022, 33, 143-156.	1.0	2
420	Therapy-induced modulation of extracellular vesicles in hepatocellular carcinoma. <i>Seminars in Cancer Biology</i> , 2022, 86, 1088-1101.	4.3	3
421	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 7: PD-L1 Expression in Liquid Biopsy. <i>Journal of Personalized Medicine</i> , 2021, 11, 1312.	1.1	6
422	New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials. <i>International Journal of Biological Sciences</i> , 2022, 18, 2775-2794.	2.6	27
423	Unraveling a Conserved Conformation of the FG Loop upon the Binding of Natural Ligands to the Human and Murine PD1. <i>Journal of Physical Chemistry B</i> , 2022, 126, 1441-1446.	1.2	1
424	EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1. <i>Nature Communications</i> , 2022, 13, 866.	5.8	51
425	Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches. , 2022, 10, e003928.		10
426	Myeloid Responses to Extracellular Vesicles in Health and Disease. <i>Frontiers in Immunology</i> , 2022, 13, 818538.	2.2	2
427	Plasma extracellular vesicle derived protein profile predicting and monitoring immunotherapeutic outcomes of gastric cancer. <i>Journal of Extracellular Vesicles</i> , 2022, 11, e12209.	5.5	18



#	ARTICLE	IF	CITATIONS
428	Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2847.	1.8	19
429	Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents. , 2022, 10, e004043.		34
430	Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer. <i>Molecular Cancer</i> , 2022, 21, 86.	7.9	72
431	LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer. <i>Molecular Cancer</i> , 2022, 21, 75.	7.9	54
432	Recent advances in overcoming barriers to cell-based delivery systems for cancer immunotherapy. <i>Exploration</i> , 2022, 2, .	5.4	68
433	Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 827921.	2.2	43
434	Cell-surface tethered promiscuous biotinylators enable comparative small-scale surface proteomic analysis of human extracellular vesicles and cells. <i>ELife</i> , 2022, 11, .	2.8	16
435	Association of the rs4143815 polymorphism of PDL1 gene with HTLV-1 infection and proviral load in asymptomatic blood donors in northeast Iran. <i>Microbiology and Immunology</i> , 2022, , .	0.7	1
436	Understanding of Immune Escape Mechanisms and Advances in Cancer Immunotherapy. <i>Journal of Oncology</i> , 2022, 2022, 1-13.	0.6	13
437	Tumor Derived Extracellular Vesicles Drive T Cell Exhaustion in Tumor Microenvironment through Sphingosine Mediated Signaling and Impacting Immunotherapy Outcomes in Ovarian Cancer. <i>Advanced Science</i> , 2022, 9, e2104452.	5.6	20
438	Exosomes for Regulation of Immune Responses and Immunotherapy. <i>Journal of Nanotheranostics</i> , 2022, 3, 55-85.	1.7	16
439	IL-3 signalling in the tumour microenvironment shapes the immune response via tumour endothelial cell-derived extracellular vesicles. <i>Pharmacological Research</i> , 2022, 179, 106206.	3.1	11
440	FOXP3 Contributes to TMZ Resistance, Prognosis, and Immune Infiltration in GBM from a Novel Pyroptosis-Associated Risk Signature. <i>Disease Markers</i> , 2022, 2022, 1-21.	0.6	6
441	Making a sPLAsh: The expanding repertoire of EV signaling. <i>Cell Metabolism</i> , 2022, 34, 508-510.	7.2	1
442	Patient-Derived Tumor Organoids: New Progress and Opportunities to Facilitate Precision Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2022, 12, 872531.	1.3	16
443	Platelet Phagocytes for the Hierarchical Amplification of Antitumor Immunity in Response to Self-Generated Immune Signals. <i>Advanced Materials</i> , 2022, 34, e2109517.	11.1	31
444	Integrated microfluidic system for isolating exosome and analyzing protein marker PD-L1. <i>Biosensors and Bioelectronics</i> , 2022, 204, 113879.	5.3	28
445	An electrochemical biosensor for the assessment of tumor immunotherapy based on the detection of immune checkpoint protein programmed death ligand-1. <i>Biosensors and Bioelectronics</i> , 2022, 207, 114166.	5.3	14

#	ARTICLE	IF	CITATIONS
446	Current methods and emerging approaches for detection of programmed death ligand 1. <i>Biosensors and Bioelectronics</i> , 2022, 208, 114179.	5.3	3
447	An electrochemical biosensor for PD-L1 positive exosomes based on ultra-thin two-dimensional covalent organic framework nanosheets coupled with CRISPR-Cas12a mediated signal amplification. <i>Sensors and Actuators B: Chemical</i> , 2022, 362, 131813.	4.0	30
448	Strategies for Engineering Exosomes and Their Applications in Drug Delivery. <i>Journal of Biomedical Nanotechnology</i> , 2021, 17, 2271-2297.	0.5	12
449	Sulfisoxazole Elicits Robust Antitumour Immune Response Along with Immune Checkpoint Therapy by Inhibiting Exosomal PD-L1. <i>Advanced Science</i> , 2022, 9, e2103245.	5.6	22
450	The foundations of immune checkpoint blockade and the ipilimumab approval decennial. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 509-528.	21.5	201
451	TGF $\beta$ 2: Signaling Blockade for Cancer Immunotherapy. <i>Annual Review of Cancer Biology</i> , 2022, 6, .	2.3	7
452	Exosomal PD-L1 confers chemoresistance and promotes tumorigenic properties in esophageal cancer cells via upregulating STAT3/miR-21. <i>Gene Therapy</i> , 2023, 30, 88-100.	2.3	12
453	Extracellular Vesicles and Transforming Growth Factor $\beta$ 2 Signaling in Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 849938.	1.8	14
454	Liquid biopsy for early diagnosis of non-small cell lung carcinoma: recent research and detection technologies. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188729.	3.3	13
455	Irradiated Cell-Derived Exosomes Transmit Essential Molecules Inducing Radiation Therapy Resistance. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 192-202.	0.4	5
456	Bioprobes-regulated precision biosensing of exosomes: From the nanovesicle surface to the inside. <i>Coordination Chemistry Reviews</i> , 2022, 463, 214538.	9.5	14
468	A photoresponsive antibody-siRNA conjugate for activatable immunogene therapy of cancer. <i>Chemical Science</i> , 2022, 13, 5345-5352.	3.7	16
469	Characterization of plasma circulating small extracellular vesicles in patients with metastatic solid tumors and newly diagnosed brain metastasis. <i>Oncolmmunology</i> , 2022, 11, 2067944.	2.1	12
470	Extracellular Vesicles Mediate Immune Responses to Tissue-Associated Self-Antigens: Role in Solid Organ Transplantations. <i>Frontiers in Immunology</i> , 2022, 13, 861583.	2.2	5
471	Bio-Conjugated Magnetic-Fluorescence Nanoarchitectures for the Capture and Identification of Lung-Tumor-Derived Programmed Cell Death Lighand 1-Positive Exosomes. <i>ACS Omega</i> , 2022, 7, 16035-16042.	1.6	5
472	The biogenesis and secretion of exosomes and multivesicular bodies (MVBs): Intercellular shuttles and implications in human diseases. <i>Genes and Diseases</i> , 2023, 10, 1894-1907.	1.5	25
473	Gp350-anchored extracellular vesicles: promising vehicles for delivering therapeutic drugs of B cell malignancies. <i>Asian Journal of Pharmaceutical Sciences</i> , 2022, 17, 462-474.	4.3	6
474	Exosomes and ferroptosis: roles in tumour regulation and new cancer therapies. <i>PeerJ</i> , 2022, 10, e13238.	0.9	7

#	ARTICLE	IF	CITATIONS
475	Engineered nanomedicines block the PD-1/PD-L1 axis for potentiated cancer immunotherapy. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 2749-2758.	2.8	16
476	Extracellular Vesicles—A New Potential Player in the Immunology of Renal Cell Carcinoma. <i>Journal of Personalized Medicine</i> , 2022, 12, 772.	1.1	1
477	Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction. <i>Clinical Cancer Research</i> , 2022, 28, 3021-3031.	3.2	32
478	CD73 in small extracellular vesicles derived from HNSCC defines tumour-associated immunosuppression mediated by macrophages in the microenvironment. <i>Journal of Extracellular Vesicles</i> , 2022, 11, e12218.	5.5	31
480	Immunosuppressive Extracellular Vesicles as a Linking Factor in the Development of Tumor and Endometriotic Lesions in the Gynecologic Tract. <i>Cells</i> , 2022, 11, 1483.	1.8	4
481	Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear sPD-L1 for immunotherapy. <i>BMJ Open</i> , 2022, 12, e050112.	0.8	6
482	Functionalized Macrophage Exosomes with Panobinostat and PPM1D-siRNA for Diffuse Intrinsic Pontine Gliomas Therapy. <i>Advanced Science</i> , 2022, 9, e2200353.	5.6	29
483	Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy. , 2022, 10, e004399.		18
484	Targeting type II <sup>3</sup> phosphatidylinositol phosphate kinase overcomes oxaliplatin resistance in colorectal cancer. <i>Theranostics</i> , 2022, 12, 4386-4398.	4.6	3
486	PD-L1 Protein Expression Is Associated With Good Clinical Outcomes and Nomogram for Prediction of Disease Free Survival and Overall Survival in Breast Cancer Patients Received Neoadjuvant Chemotherapy. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	5
487	Nasopharyngeal cancer cell-derived exosomal PD-L1 inhibits CD8 <sup>+</sup> T cell activity and promotes immune escape. <i>Cancer Science</i> , 2022, 113, 3044-3054.	1.7	20
488	Low-dose IL-2 prevents murine chronic cardiac allograft rejection: Role for IL-2-induced T regulatory cells and exosomes with PD-L1 and CD73. <i>American Journal of Transplantation</i> , 2022, 22, 2180-2194.	2.6	12
489	Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy. <i>Biomedicines</i> , 2022, 10, 1181.	1.4	8
490	Extracellular vesicles: from bench to bedside. , 2022, 1, .		3
491	The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
492	Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
493	Exosome Carrier Effects; Resistance to Digestion in Phagolysosomes May Assist Transfers to Targeted Cells; II Transfers of miRNAs Are Better Analyzed via Systems Approach as They Do Not Fit Conventional Reductionist Stoichiometric Concepts. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6192.	1.8	5
494	Plasma extracellular vesicles bearing PD-L1, CD40, CD40L or TNF-RII are significantly reduced after treatment of AIDS-NHL. <i>Scientific Reports</i> , 2022, 12, .	1.6	2

#	ARTICLE	IF	CITATIONS
495	Tumor-Derived Extracellular Vesicles Predict Clinical Outcomes in Oligometastatic Prostate Cancer and Suppress Antitumor Immunity. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 725-737.	0.4	6
496	Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with Non-small cell lung cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	39
497	Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	112
498	Exosome secretion from hypoxic cancer cells reshapes the tumor microenvironment and mediates drug resistance. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 577-94.	0.9	7
499	Extracellular vesicles in cancer therapy. <i>Seminars in Cancer Biology</i> , 2022, 86, 296-309.	4.3	23
500	The Effect of Hypoxia-Induced Exosomes on Anti-Tumor Immunity and Its Implication for Immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
501	Small extracellular vesicles derived from PD-L1-modified mesenchymal stem cell promote Tregs differentiation and prolong allograft survival. <i>Cell and Tissue Research</i> , 2022, 389, 465-481.	1.5	6
502	Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non-Small Cell Lung Cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
503	Current Status, Opportunities, and Challenges of Exosomes in Oral Cancer Diagnosis and Treatment. <i>International Journal of Nanomedicine</i> , 0, Volume 17, 2679-2705.	3.3	13
504	Small extracellular vesicle PD-L1 in cancer: the knowns and unknowns. <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	16
505	Bone Metastasis and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC): Microenvironment and Possible Clinical Implications. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6832.	1.8	15
506	Extracellular vesicle-based macromolecule delivery systems in cancer immunotherapy. <i>Journal of Controlled Release</i> , 2022, 348, 572-589.	4.8	10
507	Regulation of in vivo fate of exosomes for therapeutic applications: New frontier in nanomedicines. <i>Journal of Controlled Release</i> , 2022, 348, 483-488.	4.8	7
508	Exosome-mediated remodeling of the tumor microenvironment: From local to distant intercellular communication. <i>Cancer Letters</i> , 2022, 543, 215796.	3.2	31
509	Liquid Biopsies: Flowing Biomarkers. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 341-368.	0.8	1
510	Insight into the molecular mechanisms of gastric cancer stem cell in drug resistance of gastric cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 794-813.	0.9	2
511	HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8+ T-cell infiltration into tumors. <i>Nature Communications</i> , 2022, 13, .	5.8	23
512	Active PD-L1 incorporation within HIV virions functionally impairs T follicular helper cells. <i>PLoS Pathogens</i> , 2022, 18, e1010673.	2.1	4

#	ARTICLE	IF	CITATIONS
513	SYK Is Associated With Malignant Phenotype and Immune Checkpoints in Diffuse Glioma. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	3
514	Tumor-derived exosomes in the cancer immune microenvironment and cancer immunotherapy. <i>Cancer Letters</i> , 2022, 548, 215823.	3.2	21
515	Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies. <i>Cancers</i> , 2022, 14, 3337.	1.7	21
516	Scavenging Tumor-Derived Small Extracellular Vesicles by Functionalized 2D Materials to Inhibit Tumor Regrowth and Metastasis Following Radiotherapy. <i>Advanced Functional Materials</i> , 2022, 32, .	7.8	8
517	Generation, secretion and degradation of cancer immunotherapy target PD-L1. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	5
518	Are extracellular vesicles ready for the clinical laboratory?. <i>Laboratoriums Medizin</i> , 2022, 46, 273-282.	0.1	9
519	<sc>USP8</sc> promotes cancer progression and extracellular vesicle-mediated <sc>CD8</sc>+ T cell exhaustion by deubiquitinating the <sc>TGF</sc>- $\beta$ 2 receptor <sc>TÎ²RII</sc>. <i>EMBO Journal</i> , 2022, 41, .	3.5	20
520	Exosomes in urological diseases - Biological functions and clinical applications. <i>Cancer Letters</i> , 2022, 544, 215809.	3.2	10
521	Extracellular vesicles engineered to bind albumin demonstrate extended circulation time and lymph node accumulation in mouse models. <i>Journal of Extracellular Vesicles</i> , 2022, 11, .	5.5	20
522	A secretory form of Parkin-independent mitophagy contributes to the repertoire of extracellular vesicles released into the tumour interstitial fluid in vivo. <i>Journal of Extracellular Vesicles</i> , 2022, 11, .	5.5	4
523	Targeted Therapy of Lung Adenocarcinoma by the Nanoplatfrom Based on Milk Exosomes Loaded with Paclitaxel. <i>Journal of Biomedical Nanotechnology</i> , 2022, 18, 1075-1083.	0.5	9
524	Breast cancer cell-derived extracellular vesicles promote CD8+T cell exhaustion via TGF- $\beta$ 2 type II receptor signaling. <i>Nature Communications</i> , 2022, 13, .	5.8	43
525	Selective isolation of extracellular vesicles from minimally processed human plasma as a translational strategy for liquid biopsies. <i>Biomarker Research</i> , 2022, 10, .	2.8	8
526	Revealing the crosstalk between nasopharyngeal carcinoma and immune cells in the tumor microenvironment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	10
527	Role of Exosomes in Immunotherapy of Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 4036.	1.7	5
528	Tumour Derived Extracellular Vesicles: Challenging Target to Blunt Tumour Immune Evasion. <i>Cancers</i> , 2022, 14, 4020.	1.7	6
529	Lipid metabolism in ferroptosis and ferroptosis-based cancer therapy. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	10
530	Qingfei Jiedu decoction inhibits PD-L1 expression in lung adenocarcinoma based on network pharmacology analysis, molecular docking and experimental verification. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	9

#	ARTICLE	IF	CITATIONS
531	Hyperthermia combined with immune checkpoint inhibitor therapy in the treatment of primary and metastatic tumors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
532	From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	20
533	Biomarkers for response to immunotherapy in hepatobiliary malignancies. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022, 21, 413-419.	0.6	12
534	Blockade of exosome release alters HER2 trafficking to the plasma membrane and gives a boost to Trastuzumab. <i>Clinical and Translational Oncology</i> , 2023, 25, 185-198.	1.2	4
535	Roles of exosomes as drug delivery systems in cancer immunotherapy: a mini-review. <i>Discover Oncology</i> , 2022, 13, .	0.8	13
536	Extracellular vesicle-mediated immunoregulation in cancer. <i>International Journal of Hematology</i> , 0, , .	0.7	3
537	Temsirolimus Enhances Anti-Cancer Immunity by Inducing Autophagy-Mediated Degradation of the Secretion of Small Extracellular Vesicle PD-L1. <i>Cancers</i> , 2022, 14, 4081.	1.7	8
539	Vascular Smooth Muscle Cell Neutral Sphingomyelinase 2 in the Release of Exosomes and Vascular Calcification. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9178.	1.8	6
540	A shared, stochastic pathway mediates exosome protein budding along plasma and endosome membranes. <i>Journal of Biological Chemistry</i> , 2022, 298, 102394.	1.6	36
541	Combination of microtubule targeting agents with other antineoplastics for cancer treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188777.	3.3	12
542	Simultaneous detection of cancerous exosomal miRNA-21 and PD-L1 with a sensitive dual-cycling nanoprobe. <i>Biosensors and Bioelectronics</i> , 2022, 216, 114636.	5.3	16
543	Targeted inhibition of tumor-derived exosomes as a novel therapeutic option for cancer. <i>Experimental and Molecular Medicine</i> , 2022, 54, 1379-1389.	3.2	20
544	Immunotherapy resistance in esophageal cancer: Possible mechanisms and clinical implications. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
545	Development of an exosome-related and immune microenvironment prognostic signature in colon adenocarcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
546	The distinct roles of exosomes in innate immune responses and therapeutic applications in cancer. <i>European Journal of Pharmacology</i> , 2022, 933, 175292.	1.7	21
547	Downregulation of exosomal MHC-I promotes glioma cells escaping from systemic immunosurveillance. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2022, 46, 102605.	1.7	5
548	Role for exosomes with self-antigens and immune regulatory molecules in allo- and auto-immunity leading to chronic immune injury following murine kidney transplantation. <i>Transplant Immunology</i> , 2022, 75, 101702.	0.6	1
549	Antigen transfer and its effect on vaccine-induced immune amplification and tolerance. <i>Theranostics</i> , 2022, 12, 5888-5913.	4.6	8

#	ARTICLE	IF	CITATIONS
550	Cancer-associated fibroblasts as accomplices to confer therapeutic resistance in cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 0, 5, 889-901.	0.9	6
551	Systemic Regulation of Metastatic Disease by Extracellular Vesicles and Particles. , 2022, , 9-39.		0
552	Urine exosomes as biomarkers in bladder cancer diagnosis and prognosis: From functional roles to clinical significance. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
553	Upregulation of PD-L1 in Senescence and Aging. <i>Molecular and Cellular Biology</i> , 2022, 42, .	1.1	24
554	Exosomes carrying immune checkpoints, a promising therapeutic approach in cancer treatment. , 2022, 39, .		6
555	A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	4
556	Cancer as an infective disease: the role of <sc>EVs</sc> in tumorigenesis. <i>Molecular Oncology</i> , 2023, 17, 390-406.	2.1	4
557	Extracellular vesicles and particles impact the systemic landscape of cancer. <i>EMBO Journal</i> , 2022, 41, .	3.5	32
558	An immunogold single extracellular vesicular RNA and protein (<sup>Au</sup>SERP) biochip to predict responses to immunotherapy in nonâ€small cell lung cancer patients. <i>Journal of Extracellular Vesicles</i> , 2022, 11, .	5.5	16
559	High Blood Concentration of Leukocyte-Derived Extracellular Vesicles Is Predictive of Favorable Clinical Outcomes in Patients with Pancreatic Cancer: Results from a Multicenter Prospective Study. <i>Cancers</i> , 2022, 14, 4748.	1.7	3
560	Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
561	Identification of Diagnostic Exosomal LncRNA-miRNA-mRNA Biomarkers in Colorectal Cancer Based on the ceRNA Network. <i>Pathology and Oncology Research</i> , 0, 28, .	0.9	5
562	Exploiting the Innate Plasticity of the Programmed Cell Deathâ€1 (PD1) Receptor to Design Pembrolizumab H3 Loop Mimics**. <i>ChemBioChem</i> , 2022, 23, .	1.3	4
563	Blood exosome PD-L1 is associated with PD-L1 expression measured by immunohistochemistry, and lymph node metastasis in lung cancer. <i>Tissue and Cell</i> , 2022, 79, 101941.	1.0	5
564	Extracellular vesicle-based checkpoint regulation and immune state in cancer. , 2022, 39, .		10
566	Lipid-mediated delivery of CD47 siRNA aids JQ1 in ensuring simultaneous downregulation of PD-L1 and CD47 and improves antitumor immunotherapy efficacy. <i>Biomaterials Science</i> , 2022, 10, 6755-6767.	2.6	3
567	Platelet-derived TLT-1 promotes tumor progression by suppressing CD8+ T cells. <i>Journal of Experimental Medicine</i> , 2023, 220, .	4.2	14
569	Hypoxia-Regulated Tumor-Derived Exosomes and Tumor Progression: A Focus on Immune Evasion. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11789.	1.8	11

#	ARTICLE	IF	CITATIONS
570	Shedding of ciliary vesicles at a glance. <i>Journal of Cell Science</i> , 2022, 135, .	1.2	14
571	CD11c+ myeloid cell exosomes reduce intestinal inflammation during colitis. <i>JCI Insight</i> , 2022, 7, .	2.3	4
572	Fluid nanoporous microinterface enables multiscale-enhanced affinity interaction for tumor-derived extracellular vesicle detection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	18
573	miRNAs in anti-cancer drug resistance of non-small cell lung cancer: Recent advances and future potential. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	7
574	TRAIL in the Treatment of Cancer: From Soluble Cytokine to Nanosystems. <i>Cancers</i> , 2022, 14, 5125.	1.7	13
575	Systematic analysis of circRNA biomarkers for diagnosis, prognosis and therapy in colorectal cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	6
576	Effects of exosomes on tumor immunomodulation and their potential clinical applications (Review). <i>International Journal of Oncology</i> , 2022, 61, .	1.4	6
577	Extracellular Vesicles in Cancer Drug Resistance: Roles, Mechanisms, and Implications. <i>Advanced Science</i> , 2022, 9, .	5.6	28
578	Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1. , 2022, 19, 1290-1301.		13
579	T lymphocyte subsets and PD-1 expression on lymphocytes in peripheral blood of patients with non-small cell lung cancer. <i>Medicine (United States)</i> , 2022, 101, e31307.	0.4	3
580	Extracellular Vesicles Isolated from Plasma of Multiple Myeloma Patients Treated with Daratumumab Express CD38, PD-L1, and the Complement Inhibitory Proteins CD55 and CD59. <i>Cells</i> , 2022, 11, 3365.	1.8	4
581	Tumor-derived extracellular vesicles modulate innate immune responses to affect tumor progression. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
582	Single-Step and Highly Sensitive Imaging of Exosomal PD-L1 through Aptamer-Activated Cascade Primer Exchange Reaction-Generated Branched DNA Nanostructures. <i>ACS Sensors</i> , 2022, 7, 3571-3579.	4.0	13
583	Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer. <i>Molecular Cancer</i> , 2022, 21, .	7.9	109
584	Complex RNA world in small extracellular vesicles for liquid biopsy in cancer management. , 2022, 1, 100015.		4
585	TP53 mutation-associated immune infiltration and a novel risk score model in HNSCC. <i>Biochemistry and Biophysics Reports</i> , 2022, 32, 101359.	0.7	1
586	The Stem Cell Continuum Model and Implications in Cancer. , 2022, , 1255-1278.		0
587	Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma. <i>Clinical Cancer Research</i> , 2023, 29, 659-666.	3.2	6



#	ARTICLE	IF	CITATIONS
588	Mechanism of exosomes in the tumor microenvironment in the abscopal effect (Review). <i>International Journal of Oncology</i> , 2022, 62, .	1.4	1
590	Large tumour-derived extracellular vesicles as prognostic indicators of metastatic cancer patient survival. <i>British Journal of Cancer</i> , 2023, 128, 471-473.	2.9	1
591	The application of exosomes in the treatment of triple-negative breast cancer. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	8
592	Reprogramming of T cell-derived small extracellular vesicles using IL2 surface engineering induces potent anti-cancer effects through miRNA delivery. <i>Journal of Extracellular Vesicles</i> , 2022, 11, .	5.5	17
593	LATPS, a novel prognostic signature based on tumor microenvironment of lung adenocarcinoma to better predict survival and immunotherapy response. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
595	Organism-Generated Biological Vesicles In Situ: An Emerging Drug Delivery Strategy. <i>Advanced Science</i> , 2023, 10, .	5.6	5
596	Extracellular Vesicles and Their Roles in the Tumor Immune Microenvironment. <i>Journal of Clinical Medicine</i> , 2022, 11, 6892.	1.0	8
597	Modern aspects of immunotherapy with checkpoint inhibitors in melanoma. <i>Medical Alphabet</i> , 2022, , 35-40.	0.0	2
598	Dissecting exosome inhibitors: therapeutic insights into small-molecule chemicals against cancer. <i>Experimental and Molecular Medicine</i> , 2022, 54, 1833-1843.	3.2	17
599	Discovery of pyrazole-carbohydrazide with indole moiety as tubulin polymerization inhibitors and anti-tumor candidates. <i>Drug Development Research</i> , 2023, 84, 110-120.	1.4	1
601	Aptamer-Assisted Traceless Isolation of PD-L1-Positive Small Extracellular Vesicles for Dissecting Their Subpopulation Signature and Function. <i>Analytical Chemistry</i> , 0, , .	3.2	3
602	Novel insight into miRNA biology and its role in the pathogenesis of systemic lupus erythematosus. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
603	Manipulation of PD-L1 Endosomal Trafficking Promotes Anticancer Immunity. <i>Advanced Science</i> , 2023, 10, .	5.6	6
604	Potential Role of Tumor-Derived Exosomes in Non-Small-Cell Lung Cancer in the Era of Immunotherapy. <i>Life</i> , 2022, 12, 2104.	1.1	5
605	Tumor-derived extracellular vesicles in the colorectal cancer immune environment and immunotherapy. , 2023, 241, 108332.		4
606	Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti-PD-1 and Anti-PD-L1 Treatment in a Checkpoint Refractory Melanoma Model. <i>Cancer Immunology Research</i> , 2023, 11, 217-227.	1.6	4
607	Tumor-Derived Extracellular Vesicles in Cancer Immunoediting and Their Potential as Oncoimmunotherapeutics. <i>Cancers</i> , 2023, 15, 82.	1.7	5
608	Targeting inorganic nanoparticles to tumors using biological membrane-coated technology. <i>MedComm</i> , 2022, 3, .	3.1	5

#	ARTICLE	IF	CITATIONS
609	Suppression of PD-L1 release from small extracellular vesicles promotes systemic anti-tumor immunity by targeting ORAI1 calcium channels. <i>Journal of Extracellular Vesicles</i> , 2022, 11, .	5.5	7
610	HRS Regulates Small Extracellular Vesicle PD-L1 Secretion and Is Associated with Anti-PD-1 Treatment Efficacy. <i>Cancer Immunology Research</i> , 2023, 11, 228-240.	1.6	5
611	Immunogenic Nanovesicle-Tandem-Augmented Chemoimmunotherapy via Efficient Cancer-Homing Delivery and Optimized Ordinal-Interval Regime. <i>Advanced Science</i> , 2023, 10, .	5.6	10
612	Identifying the Phenotypes of Tumor-Derived Extracellular Vesicles Using Size-Coded Affinity Microbeads. <i>Journal of the American Chemical Society</i> , 2022, 144, 23483-23491.	6.6	18
613	Immunosuppressive Extracellular Vesicles in CLL. <i>Blood Cancer Discovery</i> , 2023, 4, 5-7.	2.6	1
614	Extracellular vesicles and melanoma: New perspectives on tumor microenvironment and metastasis. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	3
615	Thiolate DNAzymes on Gold Nanoparticles for Isothermal Amplification and Detection of Mesothelioma-derived Exosomal PD-L1 mRNA. <i>Analytical Chemistry</i> , 2023, 95, 3228-3237.	3.2	2
616	Immune evasion in esophageal squamous cell cancer: From the perspective of tumor microenvironment. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
617	A soluble pH-responsive host-guest-based nanosystem for homogeneous exosomes capture with high-efficiency. <i>Chinese Chemical Letters</i> , 2023, 34, 108129.	4.8	1
618	Extracellular Vesicles Are Important Mediators That Regulate Tumor Lymph Node Metastasis via the Immune System. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1362.	1.8	3
619	Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
620	Anti-angiogenic effect of exo-LncRNA TUG1 in myocardial infarction and modulation by remote ischemic conditioning. <i>Basic Research in Cardiology</i> , 2023, 118, .	2.5	7
621	Exosomes and cancer immunotherapy: A review of recent cancer research. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
622	Pan-Cancer Analysis of the Roles and Driving Forces of RAB42. <i>Biomolecules</i> , 2023, 13, 43.	1.8	0
623	Role of Extracellular Vesicles in Cancer Pathogenesis. , 2023, , 1-29.		0
624	Radiation-induced PD-L1 expression in tumor and its microenvironment facilitates cancer-immune escape: a narrative review. <i>Annals of Translational Medicine</i> , 2022, 10, 1406-1406.	0.7	13
625	Cancer Exosomes: An Overview and the Applications of Flow. <i>Fluids</i> , 2023, 8, 7.	0.8	0
626	Passive Membrane Permeability of Sizable Acyclic $\beta$ -Hairpin Peptides. <i>ACS Medicinal Chemistry Letters</i> , 2023, 14, 278-284.	1.3	1

#	ARTICLE	IF	CITATIONS
627	Yin and yang roles of B lymphocytes in solid tumors: Balance between antitumor immunity and immune tolerance/immunosuppression in tumor-draining lymph nodes. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
628	Mechanisms driving the immunoregulatory function of cancer cells. <i>Nature Reviews Cancer</i> , 2023, 23, 193-215.	12.8	40
629	Exosome Release Delays Senescence by Disposing of Obsolete Biomolecules. <i>Advanced Science</i> , 2023, 10, .	5.6	8
630	Cancer stem cell-derived extracellular vesicles preferentially target MHC-IIâ€‘macrophages and PD1+ T cells in the tumor microenvironment. <i>PLoS ONE</i> , 2023, 18, e0279400.	1.1	6
631	The combination of eddy thermal effect of biodegradable magnesium with immune checkpoint blockade shows enhanced efficacy against osteosarcoma. <i>Bioactive Materials</i> , 2023, 25, 73-85.	8.6	5
632	Optimization of cancer immunotherapy on the basis of programmed death ligandâ€‘1 distribution and function. <i>British Journal of Pharmacology</i> , 2024, 181, 257-272.	2.7	4
633	A glycosylation signature for predicting the progression and immunotherapeutic response of prostate cancer. <i>Journal of Gene Medicine</i> , 2023, 25, .	1.4	2
634	Extracellular vesicles: A dive into their role in the tumor microenvironment and cancer progression. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	5
635	Tumor-Derived PD-L1<sup>+</sup> Exosomes with Natural Inflammation Tropism for Psoriasis-Targeted Treatment. <i>Bioconjugate Chemistry</i> , 0, , .	1.8	2
636	Colorectal cancer-derived extracellular vesicles containing HSP70 enhance macrophage phagocytosis by up-regulating MARCO expression. <i>Experimental Cell Research</i> , 2023, 426, 113565.	1.2	3
637	Extracellular vesicles as next generation immunotherapeutics. <i>Seminars in Cancer Biology</i> , 2023, 90, 73-100.	4.3	16
638	Melatonin enhances anti-tumor immunity by targeting macrophages PD-L1 via exosomes derived from gastric cancer cells. <i>Molecular and Cellular Endocrinology</i> , 2023, 568-569, 111917.	1.6	4
639	The role of exosomes in the stemness maintenance and progression of acute myeloid leukemia. <i>Biochemical Pharmacology</i> , 2023, 212, 115539.	2.0	5
640	A Fluid Multivalent Magnetic Interface for Highâ€‘Performance Isolation and Proteomic Profiling of Tumorâ€‘Derived Extracellular Vesicles. <i>Angewandte Chemie</i> , 2023, 135, .	1.6	0
641	The Roles of Exosomal Proteins: Classification, Function, and Applications. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3061.	1.8	7
642	Hypoxia promotes EV secretion by impairing lysosomal homeostasis in HNSCC through negative regulation of ATP6V1A by HIFâ€‘1â€‘. <i>Journal of Extracellular Vesicles</i> , 2023, 12, .	5.5	7
643	Extracellular Vesicles in Cancer Drug Resistance: Implications on Melanoma Therapy. <i>Cancers</i> , 2023, 15, 1074.	1.7	2
644	Self-calibrated magnetic aptamer sensor with dual Lanthanide-assisted Time-resolved luminescence for high-sensitive detection of melanoma exosomal PD-L1. <i>Materials and Design</i> , 2023, 227, 111714.	3.3	3

#	ARTICLE	IF	CITATIONS
645	Review of biomarkers for response to immunotherapy in HNSCC microenvironment. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
646	Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapy. <i>Molecular Cancer</i> , 2023, 22, .	7.9	9
647	Role of tumor microenvironment in cancer progression and therapeutic strategy. <i>Cancer Medicine</i> , 2023, 12, 11149-11165.	1.3	27
649	Bottom-Up Signal Boosting with Fractal Nanostructuring and Primer Exchange Reaction for Ultrasensitive Detection of Cancerous Exosomes. <i>ACS Sensors</i> , 2023, 8, 1308-1317.	4.0	12
650	Simultaneous Knockdown of Immune Suppressive Markers by Tumor Microenvironment-Responsive Multifaceted Prodrug Nanomedicine. <i>ACS Applied Materials &amp; Interfaces</i> , 2023, 15, 12864-12881.	4.0	2
651	LILRB2-containing small extracellular vesicles from glioblastoma promote tumor progression by promoting the formation and expansion of myeloid-derived suppressor cells. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 2179-2193.	2.0	4
652	Recent advances in extracellular vesicles in gastrointestinal cancer and lymphoma. <i>Cancer Science</i> , 2023, 114, 2230-2237.	1.7	2
653	Immune Checkpoint and Tumor Therapy. , 0, , .		0
654	Exosomal PD-L1 promotes the formation of an immunosuppressive microenvironment in gastric diffuse large B-cell lymphoma. <i>Oncology Reports</i> , 2023, 49, .	1.2	1
655	The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. <i>Cancer Cell</i> , 2023, 41, 374-403.	7.7	298
656	Neutrophil extracellular traps in tumor progression and immunotherapy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
657	Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy. <i>Theranostics</i> , 2023, 13, 1520-1544.	4.6	19
658	Advances of multi-omics applications in hepatic precancerous lesions and hepatocellular carcinoma: The role of extracellular vesicles. <i>Frontiers in Molecular Biosciences</i> , 0, 10, .	1.6	3
660	Curvature-sensing peptide inhibits tumour-derived exosomes for enhanced cancer immunotherapy. <i>Nature Materials</i> , 2023, 22, 656-665.	13.3	12
661	A Fluid Multivalent Magnetic Interface for High-Performance Isolation and Proteomic Profiling of Tumor-Derived Extracellular Vesicles. <i>Angewandte Chemie - International Edition</i> , 2023, 62, .	7.2	10
662	The link between intracellular calcium signaling and exosomal PD-L1 in cancer progression and immunotherapy. <i>Genes and Diseases</i> , 2024, 11, 321-334.	1.5	5
663	The impact of hypoxia on extracellular vesicle secretome profile of cancer. , 2023, 40, .		4
664	Evidence for RNA or protein transport from somatic tissues to the male reproductive tract in mouse. <i>ELife</i> , 0, 12, .	2.8	3

#	ARTICLE	IF	CITATIONS
665	Exosome-disrupting peptides for cancer immunotherapy. <i>Nature Materials</i> , 2023, 22, 530-531.	13.3	1
666	Tumour-derived extracellular vesicle based vaccines for melanoma treatment. <i>Drug Delivery and Translational Research</i> , 2023, 13, 1520-1542.	3.0	3
667	Homogeneous, Simple, and Direct Analysis of Exosomal PD-L1 via Aptamer-Bivalent-Cholesterol-Anchor Assembly of DNAzyme (ABCzyme) for Tumor Immunotherapy. <i>Analytical Chemistry</i> , 2023, 95, 6854-6862.	3.2	8
668	Phosphatidylserine-positive extracellular vesicles boost effector CD8 <sup>+</sup> T cell responses during viral infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	2
669	Tumor immunosuppression relief via acidity modulation combined PD-L1 siRNA for enhanced immunotherapy. , 2023, 150, 213425.		2
670	The role of extracellular vesicles in cancer. <i>Cell</i> , 2023, 186, 1610-1626.	13.5	76
673	N6-methyladenosine (m6A)-connected lncRNAs is linked to survival and immune infiltration in glioma patients. <i>Bioscience Reports</i> , 0, , .	1.1	1
674	Leveraging Exosomes as the Next-Generation Bio-Shuttles: The Next Biggest Approach against Th17 Cell Catastrophe. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7647.	1.8	2
675	Research progress of extracellular vesicles as biomarkers in immunotherapy for non-small cell lung cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
676	Dose-Dependent Effects in Plasma Oncotherapy: Critical In Vivo Immune Responses Missed by In Vitro Studies. <i>Biomolecules</i> , 2023, 13, 707.	1.8	4
701	Recent progress in exosome research: isolation, characterization and clinical applications. <i>Cancer Gene Therapy</i> , 2023, 30, 1051-1065.	2.2	11
722	The Detection of Exosomal PD-L1 in Peripheral Blood. <i>Methods in Molecular Biology</i> , 2023, , 195-212.	0.4	1
740	Accurate and Convenient Lung Cancer Diagnosis through Detection of Extracellular Vesicle Membrane Proteins via Förster Resonance Energy Transfer. <i>Nano Letters</i> , 2023, 23, 8115-8125.	4.5	4
743	Recent progress in quantitative technologies for the analysis of cancer-related exosome proteins. <i>Analyst</i> , The, 2023, 148, 4954-4966.	1.7	0
775	Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	7
813	Extracellular vesicle-mediated ferroptosis, pyroptosis, and necroptosis: potential clinical applications in cancer therapy. <i>Cell Death Discovery</i> , 2024, 10, .	2.0	2
827	Roles of exosomes in immunotherapy for solid cancers. <i>Cell Death and Disease</i> , 2024, 15, .	2.7	0